[{"symbol": "BIYA", "publishedDate": "2026-01-18 01:41:51", "publisher": "Defense World", "title": "Baiya International Group (NASDAQ:BIYA) versus Rimini Street (NASDAQ:RMNI) Head-To-Head Analysis", "image": "https://images.financialmodelingprep.com/news/baiya-international-group-nasdaqbiya-versus-rimini-street-nasdaqrmni-headtohead-20260118.jpg", "site": "defenseworld.net", "text": "Rimini Street (NASDAQ: RMNI - Get Free Report) and Baiya International Group (NASDAQ: BIYA - Get Free Report) are both small-cap computer and technology companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends. Profitability This table compares", "url": "https://www.defenseworld.net/2026/01/18/baiya-international-group-nasdaqbiya-versus-rimini-street-nasdaqrmni-head-to-head-analysis.html"}, {"symbol": "IBRX", "publishedDate": "2026-01-16 16:57:23", "publisher": "The Motley Fool", "title": "Stock Market Today, Jan. 16: ImmunityBio Soars After Anktiva Revenue Jumps 700 Percent Year Over Year", "image": "https://images.financialmodelingprep.com/news/stock-market-today-jan-16-immunitybio-soars-after-anktiva-20260116.jpg", "site": "fool.com", "text": "Explosive Anktiva sales, new cancer data, and fresh approvals are rapidly redefining this immunotherapy story, today, Jan. 16, 2026.", "url": "https://www.fool.com/coverage/stock-market-today/2026/01/16/stock-market-today-jan-16-immunitybio-soars-after-anktiva-revenue-jumps-700-percent-year-over-year/"}, {"symbol": "IBRX", "publishedDate": "2026-01-16 15:45:59", "publisher": "Seeking Alpha", "title": "ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript", "image": "https://images.financialmodelingprep.com/news/immunitybio-inc-ibrx-presents-at-44th-annual-jp-morgan-20260116.jpg", "site": "seekingalpha.com", "text": "ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript", "url": "https://seekingalpha.com/article/4860600-immunitybio-inc-ibrx-presents-at-44th-annual-j-p-morgan-healthcare-conference-transcript"}, {"symbol": "IBRX", "publishedDate": "2026-01-16 13:45:22", "publisher": "The Motley Fool", "title": "Why ImmunityBio Stock Is Skyrocketing Again Today", "image": "https://images.financialmodelingprep.com/news/why-immunitybio-stock-is-skyrocketing-again-today-20260116.jpg", "site": "fool.com", "text": "ImmunityBio announced this morning that it had reached a major enrollment threshold for one of its clinical trials. It also highlighted initial success in treating patients with Non-Hodgkin lymphoma with one of its next-gen therapies.", "url": "https://www.fool.com/investing/2026/01/16/why-immunitybio-stock-is-skyrocketing-again-today/"}, {"symbol": "VERO", "publishedDate": "2026-01-16 13:09:35", "publisher": "Benzinga", "title": "Venus Concept Stock Explodes Over 500% After Major Investor Takes Control", "image": "https://images.financialmodelingprep.com/news/venus-concept-stock-explodes-over-500-after-major-investor-20260116.jpg", "site": "benzinga.com", "text": "Venus Concept Inc. (NASDAQ: VERO) stock skyrocketed over 500% on Friday.", "url": "https://www.benzinga.com/m-a/26/01/49973833/venus-concept-stock-explodes-over-500-after-major-investor-takes-control"}, {"symbol": "IBRX", "publishedDate": "2026-01-16 12:52:36", "publisher": "Benzinga", "title": "ImmunityBio Stock Soars On Cancer Trial Progress, FDA Timeline", "image": "https://images.financialmodelingprep.com/news/immunitybio-stock-soars-on-cancer-trial-progress-fda-timeline-20260116.jpg", "site": "benzinga.com", "text": "ImmunityBio Inc. (NASDAQ: IBRX) stock has surged more than 100% year to date after the upbeat fourth-quarter preliminary results and trial data.", "url": "https://www.benzinga.com/news/health-care/26/01/49973099/immunitybio-stock-soars-on-cancer-trial-progress-fda-timeline"}, {"symbol": "PRFX", "publishedDate": "2026-01-16 11:39:14", "publisher": "Benzinga", "title": "PainReform Stock Spikes As It Rebrands, Expands Beyond Pharma With AI, Clean Energy Push", "image": "https://images.financialmodelingprep.com/news/painreform-stock-spikes-as-it-rebrands-expands-beyond-pharma-20260116.jpg", "site": "benzinga.com", "text": "Penny stock PainReform Ltd. (NASDAQ: PRFX) stock climbed on Friday following the company's recent announcement of a name change to PRF Technologies Ltd.", "url": "https://www.benzinga.com/news/health-care/26/01/49970381/painreform-stock-spikes-as-it-rebrands-expands-beyond-pharma-with-ai-clean-energy-push"}, {"symbol": "IBRX", "publishedDate": "2026-01-16 11:04:51", "publisher": "Benzinga", "title": "ImmunityBio's 700% Revenue Boom Becomes Citadel's Latest I\u2011Told\u2011You\u2011So", "image": "https://images.financialmodelingprep.com/news/immunitybios-700-revenue-boom-becomes-citadels-latest-itoldyouso-20260116.jpg", "site": "benzinga.com", "text": "Hedge funds don't need headlines to move \u2014 they need inflection points. ImmunityBio Inc (NASDAQ: IBRX) just delivered one.", "url": "https://www.benzinga.com/markets/hedge-funds/26/01/49969034/immunitybios-700-revenue-boom-becomes-citadels-latest-i%e2%80%91told%e2%80%91you%e2%80%91so"}, {"symbol": "IBRX", "publishedDate": "2026-01-16 10:48:06", "publisher": "Proactive Investors", "title": "ImmunityBio shares rise on positive CAR-NK trial results in Waldenstr\u00f6m lymphoma", "image": "https://images.financialmodelingprep.com/news/immunitybio-shares-rise-on-positive-carnk-trial-results-in-20260116.jpg", "site": "proactiveinvestors.com", "text": "Shares of ImmunityBio (NASDAQ:IBRX) traded more than 30% higher after the company reported updated clinical data showing durable complete responses in patients treated with its off-the-shelf CD19 CAR-NK cell therapy in Waldenstr\u00f6m non-Hodgkin's lymphoma, adding to recent momentum driven by strong sales growth for its approved immunotherapy Anktiva. ImmunityBio said on Friday that follow-up from its ongoing Phase 1/2 QUILT-106 study demonstrated sustained complete responses lasting up to 15 months in evaluable patients, with 100% disease control observed to date.", "url": "https://www.proactiveinvestors.com/companies/news/1085771"}, {"symbol": "IBRX", "publishedDate": "2026-01-16 08:15:00", "publisher": "Proactive Investors - Finance", "title": "Nasdaq, Dow Jones little changed as TSMC settles tech jitters", "image": "https://images.financialmodelingprep.com/news/nasdaq-dow-jones-little-changed-as-tsmc-settles-tech-20260116.jpeg", "site": "proactiveinvestors.com", "text": "1:15pm: Market movers Shares of ImmunityBio (NASDAQ:IBRX) traded more than 30% higher after the company reported updated clinical data showing durable...", "url": "https://www.proactiveinvestors.com/companies/news/1085756/nasdaq-dow-jones-little-changed-as-tsmc-settles-tech-jitters-1085756.html"}, {"symbol": "LCFY", "publishedDate": "2026-01-16 08:00:00", "publisher": "GlobeNewsWire", "title": "Experience.com Expands U.S. Partnership with Locafy to Drive Localizer Product Sales Across Home Services Market in 2026", "image": "https://images.financialmodelingprep.com/news/experiencecom-expands-us-partnership-with-locafy-to-drive-localizer-20260116.jpg", "site": "globenewswire.com", "text": "PERTH, Australia, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Locafy Limited (Nasdaq: LCFY, LCFYW) (\u201cLocafy\u201d or the \u201cCompany\u201d), a global software-as-a-service technology company specializing in location-based digital marketing solutions, today announced the formal expansion of its partnership with Experience.com, under which Experience will sell Locafy's Localizer product across the United States.", "url": "https://www.globenewswire.com/news-release/2026/01/16/3220289/0/en/Experience-com-Expands-U-S-Partnership-with-Locafy-to-Drive-Localizer-Product-Sales-Across-Home-Services-Market-in-2026.html"}, {"symbol": "JFBR", "publishedDate": "2026-01-16 07:32:00", "publisher": "GlobeNewsWire", "title": "Jeffs' Brands: KeepZone AI Enters into a Distribution Agreement with Advanced Vehicle and Threat Detection Systems Developer", "image": "https://images.financialmodelingprep.com/news/jeffs-brands-keepzone-ai-enters-into-a-distribution-agreement-20260116.jpg", "site": "globenewswire.com", "text": "Tel Aviv, Israel, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd ( \u201c Jeffs ' Brands \u201d or the \u201c Company \u201d ) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace expanding into the global homeland security sector through advanced artificial intelligence ( \u201c AI \u201d )-driven solutions , today announced that its wholly-owned subsidiary, KeepZone AI Inc. ( \u201c KeepZone \u201d ), has entered into a non-exclusive distribution agreement (the \u201c Agreement \u201d ) with STI Ltd. ( \u201c STI \u201d ), an Israeli developer of specialized homeland security technologies. The Agreement adds to KeepZone ' s growing portfolio of integrated security solutions, with a focus on under-vehicle inspection systems, explosives detection devices, and other advanced threat detection tools.", "url": "https://www.globenewswire.com/news-release/2026/01/16/3220261/0/en/Jeffs-Brands-KeepZone-AI-Enters-into-a-Distribution-Agreement-with-Advanced-Vehicle-and-Threat-Detection-Systems-Developer.html"}, {"symbol": "IBRX", "publishedDate": "2026-01-16 07:00:00", "publisher": "Business Wire", "title": "ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma", "image": "https://images.financialmodelingprep.com/news/immunitybio-announces-durable-complete-response-of-15-months-with-20260116.jpg", "site": "businesswire.com", "text": "CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced updated efficacy and safety results from the ongoing QUILT-106 clinical study (NCT06334991) evaluating an off-the-shelf allogeneic CD19 chimeric antigen receptor natural killer cell therapy (CAR-NK). This CD19 t-haNK (CAR-NK) is a targeted high-affinity natural killer (NK) cell therapy engineered to express a CD19-specifc chimeric antigen receptor (CAR) used in combi.", "url": "https://www.businesswire.com/news/home/20260116046721/en/ImmunityBio-Announces-Durable-Complete-Response-of-15-Months-with-a-Chemotherapy-Free-CD19-CAR-NK-Cell-Therapy-in-Waldenstrom-Lymphoma/"}, {"symbol": "IBRX", "publishedDate": "2026-01-16 07:00:00", "publisher": "Business Wire", "title": "ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA\u00ae Plus BCG", "image": "https://images.financialmodelingprep.com/news/immunitybio-advances-firstline-bcg-naive-nmibc-program-with-enrollment-20260116.jpg", "site": "businesswire.com", "text": "CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced an update on the status of enrollment in its randomized registrational trial in BCG-na\u00efve non-muscle-invasive bladder cancer (NMIBC), QUILT-2.005. Enrollment has exceeded internal expectations and is now over 85% complete, with full enrollment of the planned study population anticipated by Q2 2026. Based on the current enrollment trajectory, ImmunityBio anticipates submitting a biologics license application (.", "url": "https://www.businesswire.com/news/home/20260116479411/en/ImmunityBio-Advances-First-Line-BCG-Naive-NMIBC-Program-with-Enrollment-Exceeding-Expectations-and-Positive-Interim-Analysis-for-ANKTIVA%C2%AE-Plus-BCG/"}, {"symbol": "IBRX", "publishedDate": "2026-01-16 05:52:00", "publisher": "Barrons", "title": "This Biotech Stock Is Up 100% This Year. Why It's Soaring Again Today.", "image": "https://images.financialmodelingprep.com/news/this-biotech-stock-is-up-100-this-year-why-20260116.jpg", "site": "barrons.com", "text": "The shares have climbed on every trading day so far in 2026. The streak looks set to continue.", "url": "https://www.barrons.com/articles/biotech-stock-immunitybio-cancer-drug-84f69281"}, {"symbol": "IBRX", "publishedDate": "2026-01-16 05:46:21", "publisher": "Benzinga", "title": "Stock Market Today: Dow Jones, S&P 500 Futures Gain Following Stellar Chipmaker Rally\u2014Chevron, Paysafe, J.B. Hunt Transport In Focus", "image": "https://images.financialmodelingprep.com/news/stock-market-today-dow-jones-sp-500-futures-gain-20260116.jpeg", "site": "feeds.benzinga.com", "text": "U.S. stock futures rose on Friday following Thursday's positive close. Futures of major benchmark indices were higher.", "url": "https://www.benzinga.com/markets/equities/26/01/49959070/stock-market-today-dow-jones-sp-500-futures-gain-following-stellar-chipmaker-rally-chevron-paysa"}, {"symbol": "IBRX", "publishedDate": "2026-01-16 05:45:00", "publisher": "Proactive Investors - Finance", "title": "ImmunityBio shares rise on positive CAR-NK trial results in Waldenstr\u00f6m lymphoma", "image": "https://images.financialmodelingprep.com/news/immunitybio-shares-rise-on-positive-carnk-trial-results-in-20260116.jpeg", "site": "proactiveinvestors.com", "text": "Shares of ImmunityBio (NASDAQ:IBRX) traded more than 30% higher after the company reported updated clinical data showing durable complete responses in...", "url": "https://www.proactiveinvestors.com/companies/news/1085771/immunitybio-shares-rise-on-positive-car-nk-trial-results-in-waldenstroem-lymphoma-1085771.html"}, {"symbol": "IBRX", "publishedDate": "2026-01-15 17:27:55", "publisher": "The Motley Fool", "title": "Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700%", "image": "https://images.financialmodelingprep.com/news/stock-market-today-jan-15-immunitybio-surges-after-anktiva-20260115.jpg", "site": "fool.com", "text": "On Jan. 15, 2026, investors took note of Anktiva's explosive sales ramp, its geographic expansion potential, and a possible new indication.", "url": "https://www.fool.com/coverage/stock-market-today/2026/01/15/stock-market-today-jan-15-immunitybio-surges-after-anktiva-revenue-jumps-700-percent/"}, {"symbol": "PRFX", "publishedDate": "2026-01-15 16:05:00", "publisher": "GlobeNewsWire", "title": "PainReform Ltd. Changes Name to PRF Technologies Ltd.", "image": "https://images.financialmodelingprep.com/news/painreform-ltd-changes-name-to-prf-technologies-ltd-20260115.jpg", "site": "globenewswire.com", "text": "Shareholders Approved Name Change at January 6, 2026 Annual General Meeting as Company Evolves Beyond Single-Asset Focus Shareholders Approved Name Change at January 6, 2026 Annual General Meeting as Company Evolves Beyond Single-Asset Focus", "url": "https://www.globenewswire.com/news-release/2026/01/15/3219986/0/en/PainReform-Ltd-Changes-Name-to-PRF-Technologies-Ltd-Reflecting-Expansion-into-Diversified-Healthcare-and-AI-Driven-Energy-Platforms.html"}, {"symbol": "IBRX", "publishedDate": "2026-01-15 12:50:37", "publisher": "Seeking Alpha", "title": "ImmunityBio: Why I Am Upgrading To A Buy For 2026", "image": "https://images.financialmodelingprep.com/news/immunitybio-why-i-am-upgrading-to-a-buy-for-20260115.jpg", "site": "seekingalpha.com", "text": "ImmunityBio is upgraded to Buy for 2026, reflecting improving Anktiva data and potential label expansions in NMIBC and NSCLC. IBRX reported 2025 product revenue of $113m, up 700% year-on-year, but losses remain heavy and commercial traction is not yet spectacular. Anktiva shows superior duration of response versus competitors and promising survival data in NSCLC, supporting long-term revenue potential.", "url": "https://seekingalpha.com/article/4860211-immunitybio-why-i-am-upgrading-to-buy-for-2026"}, {"symbol": "IBRX", "publishedDate": "2026-01-15 12:43:56", "publisher": "Benzinga", "title": "ImmunityBio Clocks 700% Revenue Surge In 2025 From Lead Bladder Cancer Drug", "image": "https://images.financialmodelingprep.com/news/immunitybio-clocks-700-revenue-surge-in-2025-from-lead-20260115.jpg", "site": "benzinga.com", "text": "ImmunityBio, Inc. (NASDAQ: IBRX) shares are up on Thursday as the company is reporting continued execution and sales momentum, with a significant increase in preliminary net product revenue.", "url": "https://www.benzinga.com/markets/earnings/26/01/49945085/immunitybio-clocks-700-revenue-surge-in-2025-from-lead-bladder-cancer-drug"}, {"symbol": "IBRX", "publishedDate": "2026-01-15 08:30:00", "publisher": "Business Wire", "title": "ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue\u2014a 700% increase year-over-year", "image": "https://images.financialmodelingprep.com/news/immunitybio-reports-continued-execution-and-sales-momentum-with-113-20260115.jpg", "site": "businesswire.com", "text": "CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a vertically-integrated commercial stage biotechnology company, announced today preliminary select operational results for the fiscal quarter and full year ending December 31, 2025. ImmunityBio reported preliminary net product revenue of approximately $38.3 million during the three-month period ending December 31, 2025, which represented an increase of 20% over the $31.8 million of net product revenue earned during the thir.", "url": "https://www.businesswire.com/news/home/20260115898106/en/ImmunityBio-Reports-Continued-Execution-and-Sales-Momentum-With-113-Million-of-Preliminary-Net-Product-Revenue%E2%80%94a-700-increase-year-over-year/"}, {"symbol": "JFBR", "publishedDate": "2026-01-15 02:16:47", "publisher": "Defense World", "title": "Analyzing QVC Group (NASDAQ:QVCGA) and Jeffs\u2019 Brands (NASDAQ:JFBR)", "image": "https://images.financialmodelingprep.com/news/analyzing-qvc-group-nasdaqqvcga-and-jeffs-brands-nasdaqjfbr-20260115.png", "site": "defenseworld.net", "text": "QVC Group (NASDAQ: QVCGA - Get Free Report) and Jeffs' Brands (NASDAQ: JFBR - Get Free Report) are both small-cap retail/wholesale companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations. Profitability This table compares QVC Group and", "url": "https://www.defenseworld.net/2026/01/15/analyzing-qvc-group-nasdaqqvcga-and-jeffs-brands-nasdaqjfbr.html"}, {"symbol": "JAGX", "publishedDate": "2026-01-14 09:00:00", "publisher": "Accesswire", "title": "Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts", "image": "https://images.financialmodelingprep.com/news/jaguar-health-presenting-january-15-at-lytham-partners-healthcare-20260114.jpg", "site": "accessnewswire.com", "text": "SAN FRANCISCO, CA / ACCESS Newswire / January 14, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday, January 15, 2026 at the Lytham Partners Healthcare Investor Summit. Participation Instructions for Jaguar's Virtual Presentation at the Lytham Partners Healthcare Investor Summit When: Thursday, January 15, 2026 at 3:30 PM Eastern Registration link for conference: Click Here Replay: A replay of the webcast will be available through the same link (Click Here) About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain.", "url": "https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-presenting-january-15-at-lytham-partners-healthcare-inv-1126943"}, {"symbol": "IBRX", "publishedDate": "2026-01-14 08:30:00", "publisher": "Business Wire", "title": "Saudi FDA Grants Accelerated Approval to ImmunityBio's ANKTIVA\u00ae for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ", "image": "https://images.financialmodelingprep.com/news/saudi-fda-grants-accelerated-approval-to-immunitybios-anktiva-for-20260114.jpg", "site": "businesswire.com", "text": "CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug Authority (SFDA) has granted approval of ANKTIVA\u00ae (nogapendekin alfa inbakicept) plus Bacillus Calmette-Gu\u00e9rin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ, with or without papillary disease. This regulatory action by the SFDA adds to the existing approvals in the Uni.", "url": "https://www.businesswire.com/news/home/20260114174640/en/Saudi-FDA-Grants-Accelerated-Approval-to-ImmunityBio%E2%80%99s-ANKTIVA%C2%AE-for-Non-Muscle-Invasive-Bladder-Cancer-with-Carcinoma-In-Situ/"}, {"symbol": "IBRX", "publishedDate": "2026-01-14 08:30:00", "publisher": "Business Wire", "title": "Saudi FDA Grants Accelerated Approval to ImmunityBio's ANKTIVA\u00ae In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer", "image": "https://images.financialmodelingprep.com/news/saudi-fda-grants-accelerated-approval-to-immunitybios-anktiva-in-20260114.jpg", "site": "businesswire.com", "text": "CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug Authority (SFDA) has granted accelerated approval of ANKTIVA\u00ae (nogapendekin alfa inbakicept) for use in combination with immune checkpoint inhibitors for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose disease has progressed following standard-of-care therapy. This marks the first approval of the C.", "url": "https://www.businesswire.com/news/home/20260114097481/en/Saudi-FDA-Grants-Accelerated-Approval-to-ImmunityBio%E2%80%99s-ANKTIVA%C2%AE-In-Combination-with-Checkpoint-Inhibitors-for-Metastatic-Non-Small-Cell-Lung-Cancer/"}, {"symbol": "BIYA", "publishedDate": "2026-01-14 04:58:57", "publisher": "Defense World", "title": "Baiya International Group Inc. (NASDAQ:BIYA) Sees Significant Decline in Short Interest", "image": "https://images.financialmodelingprep.com/news/baiya-international-group-inc-nasdaqbiya-sees-significant-decline-in-20260114.png", "site": "defenseworld.net", "text": "Baiya International Group Inc. (NASDAQ: BIYA - Get Free Report) was the recipient of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totaling 15,748 shares, a decrease of 97.6% from the December 15th total of 654,832 shares. Approximately 1.3% of the company's shares are sold", "url": "https://www.defenseworld.net/2026/01/14/baiya-international-group-inc-nasdaqbiya-sees-significant-decline-in-short-interest.html"}, {"symbol": "IBRX", "publishedDate": "2026-01-13 08:30:00", "publisher": "Business Wire", "title": "ImmunityBio Announces Positive Results Demonstrating ANKTIVA\u00ae as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer", "image": "https://images.financialmodelingprep.com/news/immunitybio-announces-positive-results-demonstrating-anktiva-as-a-lymphocyte-20260113.jpg", "site": "businesswire.com", "text": "CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA (nogapendekin alfa inbakicept) clinical program in non-small cell lung cancer (NSCLC) based on two studies, QUILT-2.023 and QUILT-3.055. Across 151 patients spanning first-, second-, and later-line disease, ANKTIVA demonstrated statistically significant immune restoration and a consistent association between lymphocyte recovery and imp.", "url": "https://www.businesswire.com/news/home/20260113762801/en/ImmunityBio-Announces-Positive-Results-Demonstrating-ANKTIVA%C2%AE-as-a-Lymphocyte-Stimulating-Agent-in-Combination-With-Checkpoint-Inhibitors-in-Non-Small-Cell-Lung-Cancer/"}, {"symbol": "TNMG", "publishedDate": "2026-01-13 07:00:00", "publisher": "PRNewsWire", "title": "TNL Mediagene Announces Conclusion of GIZMART's Debut Project \"Keychron Nape Pro,\" Surpassing \u00a5300 Million in GMV", "image": "https://images.financialmodelingprep.com/news/tnl-mediagene-announces-conclusion-of-gizmarts-debut-project-keychron-20260113.jpg", "site": "prnewswire.com", "text": "\u2013 GIZMART's first project concludes with over \u00a5300 million in GMV, validating the monetization and scalability of the Company's digital media-commerce strategy \u2013Jointly developed in collaboration with global keyboard and peripheral device brand Keychron, the project demonstrates the Company's ability to monetize its platform through collaborative digital media-commerce initiatives \u2013 The project demonstrated sustained momentum beyond initial launch, following \u00a5100 million in GMV achieved within the first 12 hours \u2013 Live commerce and continuous editorial engagement contributed to user trust and conversion throughout the campaign period TOKYO, Jan. 13, 2026 /PRNewswire/ -- TNL Mediagene (Nasdaq: TNMG) (the \"Company\"), a Tokyo-based next-generation digital media and data group in Asia, today announced that the crowdfunding campaign for Keychron Nape Pro, the debut project of its digital media-commerce platform GIZMART has concluded with gross merchandise value (\"GMV\") exceeding \u00a5300 million. Jointly developed in collaboration with global keyboard and peripheral device brand Keychron, the Keychron Nape Pro project demonstrates the Company's ability to monetize its platform through collaborative digital media-commerce initiatives.", "url": "https://www.prnewswire.com/news-releases/tnl-mediagene-announces-conclusion-of-gizmarts-debut-project-keychron-nape-pro-surpassing-300-million-in-gmv-302659678.html"}, {"symbol": "JFBR", "publishedDate": "2026-01-12 09:28:00", "publisher": "GlobeNewsWire", "title": "Jeffs' Brands: KeepZone AI Aims to Transform Homeland Security as a One-Stop Shop for Integrated Solutions", "image": "https://images.financialmodelingprep.com/news/jeffs-brands-keepzone-ai-aims-to-transform-homeland-security-20260112.jpg", "site": "globenewswire.com", "text": "Tel Aviv, Israel, Jan. 12, 2026 (GLOBE NEWSWIRE) -- As global security threats become increasingly sophisticated, the demand for advanced, AI-driven homeland security solutions has never been higher. KeepZone AI Inc. (\u201cKeepZone\u201d), a wholly owned subsidiary of Jeffs' Brands Ltd (\u201cJeffs' Brands\u201d or the \u201cCompany\u201d) (Nasdaq: JFBR, JFBRW), was launched as part of Jeffs' Brands' strategic expansion beyond its legacy date-driven e-commerce operations into the global homeland security sector through advanced artificial intelligence (\u201cAI\u201d)-driven solutions. KeepZone aims to integrate multiple innovative systems into seamless, multi-layered ecosystems designed to address modern challenges such as border protection, critical infrastructure safeguarding, and public safety.", "url": "https://www.globenewswire.com/news-release/2026/01/12/3217041/0/en/Jeffs-Brands-KeepZone-AI-Aims-to-Transform-Homeland-Security-as-a-One-Stop-Shop-for-Integrated-Solutions.html"}, {"symbol": "JAGX", "publishedDate": "2026-01-12 09:00:00", "publisher": "Accesswire", "title": "Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million", "image": "https://images.financialmodelingprep.com/news/jaguar-health-enters-into-us-license-agreement-with-future-20260112.jpg", "site": "accessnewswire.com", "text": "$18M upfront payment to Jaguar ($16M upon deal closing and $2M upon completion of post-closing conditions) Up to additional $20M in milestone and other future payments Future Pak becomes exclusive U.S. marketer for Mytesi\u00ae and Canalevia\u00ae-CA1 Jaguar continues to be the manufacturer of Mytesi and Canalevia-CA1 Meaningful non-dilutive capital enables Jaguar to focus on its rare-disease pipeline, which is the subject of ongoing BD discussions with other potential partners SAN FRANCISCO, CA / ACCESS Newswire / January 12, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that its wholly-owned subsidiary Napo Pharmaceuticals, Inc. (collectively, with Jaguar Health, Inc., \"Jaguar\") has entered into a U.S. licensing agreement with an affiliate of privately held Future Pak, LLC (\"Future Pak\"). Under the terms of the agreement, Future Pak will be the exclusive marketer for Mytesi (crofelemer), Jaguar's FDA-approved novel prescription drug for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy, and Canalevia-CA1, Jaguar's crofelemer prescription drug for the treatment of chemotherapy-induced diarrhea in dogs.", "url": "https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-enters-into-u.s.-license-agreement-with-future-pak-for-1126241"}, {"symbol": "PRFX", "publishedDate": "2026-01-12 09:00:00", "publisher": "GlobeNewsWire", "title": "PainReform's LayerBio's Drop-Less OcuRing\u2122-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical Studies", "image": "https://images.financialmodelingprep.com/news/painreforms-layerbios-dropless-ocuringk-delivery-platform-demonstrates-favorable-safety-20260112.jpg", "site": "globenewswire.com", "text": "TEL AVIV, Israel, Jan. 12, 2026 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX),\u00a0a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics for post-operative pain management, together with its majority-owned subsidiary LayerBio, Inc., today announced safety data supporting the continued development of OcuRing\u2122-K drop-less, sustained-release ocular drug delivery platform for use in cataract surgery.", "url": "https://www.globenewswire.com/news-release/2026/01/12/3216988/0/en/PainReform-s-LayerBio-s-Drop-Less-OcuRing-K-Delivery-Platform-Demonstrates-Favorable-Safety-Profile-in-Preclinical-and-Phase-I-Clinical-Studies.html"}, {"symbol": "IBRX", "publishedDate": "2026-01-12 08:30:00", "publisher": "Business Wire", "title": "NantWorks and ImmunityBio Announce Inaugural U.S.-Saudi Biotech Alliance Summit to Advance Immunotherapy 2.0 and Global Health Security", "image": "https://images.financialmodelingprep.com/news/nantworks-and-immunitybio-announce-inaugural-ussaudi-biotech-alliance-summit-20260112.jpg", "site": "businesswire.com", "text": "CULVER CITY, Calif.--(BUSINESS WIRE)--NantWorks, LLC, and ImmunityBio, Inc. (NASDAQ: IBRX), today announced the inaugural U.S.-Saudi Biotech Alliance Summit, to be held in conjunction with the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026, from 9:00 am to 5:30 pm Pacific Time. Convened by NantWorks, the Summit brings together national leaders from the United States and the Kingdom of Saudi Arabia across government, healthcare delivery, biotechnolo.", "url": "https://www.businesswire.com/news/home/20260112462615/en/NantWorks-and-ImmunityBio-Announce-Inaugural-U.S.-Saudi-Biotech-Alliance-Summit-to-Advance-Immunotherapy-2.0-and-Global-Health-Security/"}, {"symbol": "PRFX", "publishedDate": "2026-01-10 02:22:47", "publisher": "Defense World", "title": "PainReform (NASDAQ:PRFX) vs. Citius Pharmaceuticals (NASDAQ:CTXR) Financial Comparison", "image": "https://images.financialmodelingprep.com/news/painreform-nasdaqprfx-vs-citius-pharmaceuticals-nasdaqctxr-financial-comparison-20260110.png", "site": "defenseworld.net", "text": "PainReform (NASDAQ: PRFX - Get Free Report) and Citius Pharmaceuticals (NASDAQ: CTXR - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk. Insider and Institutional Ownership 37.3% of PainReform shares", "url": "https://www.defenseworld.net/2026/01/10/painreform-nasdaqprfx-vs-citius-pharmaceuticals-nasdaqctxr-financial-comparison.html"}, {"symbol": "TNMG", "publishedDate": "2026-01-07 07:00:00", "publisher": "PRNewsWire", "title": "TNL Mediagene Supports Japan's Unique, High-Value-Added Fashion IP Development with METI Partnership; Showcase Set for January 2026", "image": "https://images.financialmodelingprep.com/news/tnl-mediagene-supports-japans-unique-highvalueadded-fashion-ip-development-20260107.jpg", "site": "prnewswire.com", "text": "TNL Mediagene's subsidiary Infobahn has been selected as a Lead Partner for the Ministry of Economy, Trade and Industry of Japan (\"METI\") initiative \"The Program for Creating Global Fashion IP\" and will lead the organization of the results presentation event titled \"UNFOLDING\" in January 2026 METI's \"Program for Creating Global Fashion IP\" is part of a broader initiative by the Japanese government that focuses on boosting Japanese creative industries, including fashion, by fostering global IP value, enhancing creation, and supporting international expansion through public-private partnerships and initiatives to develop talent and connect with global brands, all aimed at turning cultural strengths into economic assets This program aims to cultivate the next generation of fashion creators and generate Japan's unique, high-value-added \"Fashion IP\" Infobahn is the Company's leading content marketing and communication company and counts some of Japan's largest multinational companies and government entities among its clients Infobahn was selected to lead this METI program due to its high level of strategic planning capabilit ies and proven track record in project execution TOKYO, Jan. 7, 2026 /PRNewswire/ -- TNL Mediagene (Nasdaq: TNMG) (the \"Company\"), a Tokyo-based next-generation digital media and data group in Asia, today announced\u00a0that its subsidiary Infobahn Inc. (\"Infobahn\") has been selected as Lead Partner for the Japanese Ministry of Economy, Trade and Industry\u00a0(\"METI\")\u00a0initiative \"The Program for Creating Global Fashion IP\" and will lead the organization of the results presentation event titled \"UNFOLDING\" in January 2026. METI is a key government body overseeing Japan's industrial policy, trade, energy security, and innovation.", "url": "https://www.prnewswire.com/news-releases/tnl-mediagene-supports-japans-unique-high-value-added-fashion-ip-development-with-meti-partnership-showcase-set-for-january-2026-302655104.html"}, {"symbol": "JAGX", "publishedDate": "2026-01-06 09:00:00", "publisher": "Accesswire", "title": "Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication", "image": "https://images.financialmodelingprep.com/news/article-about-groundbreaking-results-from-study-of-jaguar-healths-20260106.jpg", "site": "accessnewswire.com", "text": "Article discusses results demonstrating parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failure Associated with significant toxicities to patients, PS has a lethal natural history, and PS reduction can potentially extend and save lives SAN FRANCISCO, CA / ACCESS Newswire / January 6, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that an article published December 29, 2025 in HEALTH, a bi-monthly English and Arabic healthcare magazine in the United Arab Emirates, discusses the groundbreaking results of the ongoing and independent proof-of-concept study of crofelemer in pediatric patients in the UAE with intestinal failure due to the orphan diseases short bowel syndrome (SBS-IF) and microvillus inclusion disease (MVID). As announced, the initial results of this study were presented November 8, 2025 at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting by the study's primary investigator, Dr. Mohamad Miqdady, Division Chief of the Pediatric Gastroenterology, Hepatology & Nutrition Division at Sheikh Khalifa Medical City, a tertiary care center in Abu Dhabi in the UAE.", "url": "https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/article-about-groundbreaking-results-from-study-of-jaguar-healths-cro-1124314"}, {"symbol": "TNMG", "publishedDate": "2026-01-06 07:00:00", "publisher": "PRNewsWire", "title": "TNL Mediagene Introduces NLWeb Support to Strengthen Its Digital Media as AI-Native Content Infrastructure for the AI-Driven Web", "image": "https://images.financialmodelingprep.com/news/tnl-mediagene-introduces-nlweb-support-to-strengthen-its-digital-20260106.jpg", "site": "prnewswire.com", "text": "The Company has introduced Natural Language Web (\"NLWeb\") support to its digital media assets, enhancing how its content interfaces with the AI ecosystem and facilitating AI monetization opportunities NLWeb is an emerging framework introduced by Microsoft that is designed to enable websites to make content and services accessible through natural language interfaces, allowing users and AI agents to retrieve information through plain-language queries rather than traditional link-based navigation By adopting NLWeb, the Company is enabling its digital media content to be not only consumed by people, but also directly understood, queried and utilized by AI systems, positioning its media assets as on-demand content infrastructure for the AI era The introduction of NLWeb support represents an evolution in the Company's transformation into an AI-native, platform-oriented content infrastructure provider, enabling structured, conversational and scalable AI access to its digital media assets The Company views NLWeb support as a foundational capability aligned with the evolving AI-driven web, supporting the Company's long-term growth and AI platform strategy TOKYO and TAIPEI, Jan. 6, 2026 /PRNewswire/ -- TNL Mediagene (Nasdaq: TNMG) (the \"Company\"), a Tokyo-based next-generation digital media and data group in Asia, today announced that it has introduced Natural Language Web (\"NLWeb\") support to its digital media assets, enhancing how the Company's content interfaces with the AI ecosystem and facilitating AI monetization opportunities. NLWeb is an emerging framework introduced by Microsoft that is designed to enable websites to make content and services accessible through natural language interfaces for users and AI systems.", "url": "https://www.prnewswire.com/news-releases/tnl-mediagene-introduces-nlweb-support-to-strengthen-its-digital-media-as-ai-native-content-infrastructure-for-the-ai-driven-web-302653741.html"}, {"symbol": "PRFX", "publishedDate": "2026-01-05 09:00:00", "publisher": "GlobeNewsWire", "title": "PainReform's DeepSolar Launches Smart TDD, a Next-Generation Solar Due Diligence Service Targeting the $60B+ Global Solar Asset M&A Market", "image": "https://images.financialmodelingprep.com/news/painreforms-deepsolar-launches-smart-tdd-a-nextgeneration-solar-due-20260105.jpg", "site": "globenewswire.com", "text": "New lifecycle-wide audit platform provides complete data coverage, advanced diagnostics, and rapid turnaround, supporting investors, operators, insurers and lenders across commissioning, underperformance, warranty expiry, and asset transactions New lifecycle-wide audit platform provides complete data coverage, advanced diagnostics, and rapid turnaround, supporting investors, operators, insurers and lenders across commissioning, underperformance, warranty expiry, and asset transactions", "url": "https://www.globenewswire.com/news-release/2026/01/05/3212807/0/en/PainReform-s-DeepSolar-Launches-Smart-TDD-a-Next-Generation-Solar-Due-Diligence-Service-Targeting-the-60B-Global-Solar-Asset-M-A-Market.html"}, {"symbol": "JFBR", "publishedDate": "2026-01-05 08:50:00", "publisher": "GlobeNewsWire", "title": "Jeffs' Brands: KeepZone AI Expands its Homeland Security Portfolio with Entry into Representation Agreement for RT LTA Systems'sAdvanced Aerostat Systems", "image": "https://images.financialmodelingprep.com/news/jeffs-brands-keepzone-ai-expands-its-homeland-security-portfolio-20260105.jpg", "site": "globenewswire.com", "text": "Tel Aviv, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd (\u201cJeffs' Brands\u201d or the \u201cCompany\u201d) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace expanding into the global homeland security sector through advanced artificial intelligence (\u201cAI\u201d)-driven solutions, today announced that its wholly owned subsidiary, KeepZone AI Inc., (\u201cKeepZone\u201d), has entered into a representation agreement (the \u201cAgreement\u201d) with RT LTA Systems Ltd. (\u201cRT\u201d), an Israeli designer, developer, and manufacturer of the SkyStar\u2122 family of aerostats.", "url": "https://www.globenewswire.com/news-release/2026/01/05/3212797/0/en/Jeffs-Brands-KeepZone-AI-Expands-its-Homeland-Security-Portfolio-with-Entry-into-Representation-Agreement-for-RT-LTA-Systems-sAdvanced-Aerostat-Systems.html"}, {"symbol": "JAGX", "publishedDate": "2026-01-02 09:00:00", "publisher": "Accesswire", "title": "Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs", "image": "https://images.financialmodelingprep.com/news/jaguar-health-awarded-240000-fda-grant-in-support-of-20260102.jpg", "site": "accessnewswire.com", "text": "SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\") today announced that it received notice from the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) on January 1, 2026 that the company has been awarded a $240,000 grant. Canalevia-CA1 is currently conditionally approved for chemotherapy-induced diarrhea (CID) in dogs.", "url": "https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-awarded-240-000-fda-grant-in-support-of-canalevia-ca1-f-1122974"}, {"symbol": "JFBR", "publishedDate": "2026-01-02 01:54:52", "publisher": "Defense World", "title": "Jeffs\u2019 Brands (NASDAQ:JFBR) versus Prosus (OTCMKTS:PROSY) Head to Head Analysis", "image": "https://images.financialmodelingprep.com/news/jeffs-brands-nasdaqjfbr-versus-prosus-otcmktsprosy-head-to-head-20260102.jpg", "site": "defenseworld.net", "text": "Jeffs' Brands (NASDAQ: JFBR - Get Free Report) and Prosus (OTCMKTS:PROSY - Get Free Report) are both retail/wholesale companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends and valuation. Analyst Recommendations This is a breakdown of recent ratings", "url": "https://www.defenseworld.net/2026/01/02/jeffs-brands-nasdaqjfbr-versus-prosus-otcmktsprosy-head-to-head-analysis.html"}, {"symbol": "JFBR", "publishedDate": "2025-12-31 17:35:00", "publisher": "TheNewswire", "title": "Jeffs' Brands Ltd - Early Warning Regarding Acquisition Of Common Shares In Connection With Shares For Debt Transaction Of Fort Technology Inc.", "image": "https://images.financialmodelingprep.com/news/jeffs-brands-ltd-early-warning-regarding-acquisition-of-common-20251231.jpg", "site": "thenewswire.com", "text": "This press release is issued pursuant to National Instrument 62-104 \u2013 Take-Over Bids and Issuer Bids and National Instrument 62-103 \u2013 The Early Warning System and Related Take-Over Bid and Insider Reporting Issues . Vancouver, British Columbia \u2013 December\u00a031, 2025 \u2013 TheNewswire - Pursuant to the requirements of applicable securities laws, Jeffs' Brands Ltd (\u201c Jeffs' Brands \u201d), a company with an office address of 7 Mezada Street, Bnei\u00a0Brak, 5126112, Israel , reports that on December\u00a031, 2025, Jeffs' Brands acquired 3,401,603\u00a0common shares in the capital of Fort Technology Inc. (the \u201c Company \u201d) (\u201c Shares \u201d) at a deemed issue price of $0.99 per Share as full settlement of outstanding debt owed by the Company to Jeffs' Brands in the amount of USD2,462,767 (the \u201c Debt \u201d) converted into CAD3,367,587.60 based on the Bank of Canada exchange rate on December\u00a024, 2025 (the \u201c Debt Settlement \u201d). The transaction took place as an issuance from treasury with the approvals of the TSXV Venture Exchange and disinterested shareholders representing at least 50% of the Shares of the Company not held by Jeffs' Brands. .", "url": "https://www.thenewswire.com/press-releases/1LymF3RZ6-jeffs-brands-ltd-early-warning-regarding-acquisition-of-common-shares-in-connection-with-shares-for-debt-transaction-of-fort-technology-inc.html"}, {"symbol": "JFBR", "publishedDate": "2025-12-31 07:45:00", "publisher": "GlobeNewsWire", "title": "Jeffs' Brands: Fort Technology Inc. Announces Intention to List its Common Shares on the Nasdaq Capital Market", "image": "https://images.financialmodelingprep.com/news/jeffs-brands-fort-technology-inc-announces-intention-to-list-20251231.jpg", "site": "globenewswire.com", "text": "Tel Aviv, Israel, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd (\u201cJeffs' Brands\u201d or the \u201cCompany\u201d) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company strategically pivoting into homeland security, today announced that the board of directors of its majority-owned subsidiary, Fort Technology Inc. (TSXV: FORT) (\u201cFort\u201d), approved a strategic initiative to pursue an uplisting of Fort's common shares on the Nasdaq Capital Market (\u201cNasdaq\u201d).", "url": "https://www.globenewswire.com/news-release/2025/12/31/3211761/0/en/Jeffs-Brands-Fort-Technology-Inc-Announces-Intention-to-List-its-Common-Shares-on-the-Nasdaq-Capital-Market.html"}, {"symbol": "PRFX", "publishedDate": "2025-12-30 08:48:00", "publisher": "PRNewsWire", "title": "BladeRanger to Showcase Advanced Green Energy Technologies at Abu Dhabi Sustainability Week", "image": "https://images.financialmodelingprep.com/news/bladeranger-to-showcase-advanced-green-energy-technologies-at-abu-20251230.jpg", "site": "prnewswire.com", "text": "AI-driven monitoring and analytics solutions addressing the growing demand for energy efficiency in large-scale solar and critical infrastructure projects across the Middle East. TEL AVIV, Israel, Dec. 30, 2025 /PRNewswire/ -- BladeRanger\u00a0(TASE: BLRN), a provider of drone-based inspection, maintenance, and AI-driven analytics solutions for green energy and critical infrastructure, today announced its participation in Abu Dhabi Sustainability Week (ADSW), a leading global platform dedicated to sustainability, clean energy, and climate-related innovation.", "url": "https://www.prnewswire.com/news-releases/bladeranger-to-showcase-advanced-green-energy-technologies-at-abu-dhabi-sustainability-week-302650696.html"}, {"symbol": "TNMG", "publishedDate": "2025-12-30 06:30:00", "publisher": "PRNewsWire", "title": "TNL Mediagene Releases H2 and 2025 Corporate Update Presentation to Shareholders, Highlighting Growth of Technology and Digital Studio Business Units, AI Initiatives, Strategic Partnerships and Content Commerce Initiatives", "image": "https://images.financialmodelingprep.com/news/tnl-mediagene-releases-h2-and-2025-corporate-update-presentation-20251230.jpg", "site": "prnewswire.com", "text": "TOKYO and TAIPEI, Dec. 30, 2025 /PRNewswire/ -- TNL Mediagene (Nasdaq: TNMG) (the \"Company\"), a Tokyo-based next-generation digital media and data group in Asia, today released its H2 and 2025 Corporate Update Presentation to the Company's shareholders (the \"Presentation\"), outlining a summary overview of its business and recent business updates and supplementing the shareholder letter issued on December 19, 2025. The Corporate Update Presentation highlights recent business updates including: Growth of Technology and Digital Studio business units: Revenue for FY2025 is expected to be $49.1 million.", "url": "https://www.prnewswire.com/news-releases/tnl-mediagene-releases-h2-and-2025-corporate-update-presentation-to-shareholders-highlighting-growth-of-technology-and-digital-studio-business-units-ai-initiatives-strategic-partnerships-and-content-commerce-initiatives-302650644.html"}, {"symbol": "IBRX", "publishedDate": "2025-12-29 11:15:29", "publisher": "Zacks Investment Research", "title": "3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround", "image": "https://images.financialmodelingprep.com/news/3-beatendown-biotech-stocks-to-buy-for-a-2026-20251229.jpg", "site": "zacks.com", "text": "Beaten-down biotech stocks like ALT, IBRX and MCRB are eyeing a 2026 rebound as FDA alignment, pipeline progress and approvals fuel optimism.", "url": "https://www.zacks.com/stock/news/2809784/3-beaten-down-biotech-stocks-to-buy-for-a-2026-turnaround?cid=CS-STOCKNEWSAPI-FT-analyst_blog|investment_ideas-2809784"}, {"symbol": "IBRX", "publishedDate": "2025-12-29 09:00:00", "publisher": "Business Wire", "title": "ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of \u201c100 Most Influential People in Oncology in 2025\u201d", "image": "https://images.financialmodelingprep.com/news/immunitybio-founder-dr-patrick-soonshiong-recognized-as-one-of-20251229.jpg", "site": "businesswire.com", "text": "CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that OncoDaily has recognized Dr. Patrick Soon-Shiong as being one of \u201cThe 100 Most Influential People in Oncology in 2025.\u201d Soon-Shiong is the company's Founder, Executive Chairman and Global Chief Scientific and Medical Officer, and is a global thought leader in advancing the goal of a cancer-free society. On its website announcing the honor, OncoDaily highlighted.", "url": "https://www.businesswire.com/news/home/20251229462120/en/ImmunityBio-Founder-Dr.-Patrick-Soon-Shiong-Recognized-as-One-of-%E2%80%9C100-Most-Influential-People-in-Oncology-in-2025%E2%80%9D/"}, {"symbol": "VERO", "publishedDate": "2025-12-28 05:09:00", "publisher": "Defense World", "title": "Venus Concept Inc. (NASDAQ:VERO) Short Interest Down 35.0% in December", "image": "https://images.financialmodelingprep.com/news/venus-concept-inc-nasdaqvero-short-interest-down-350-in-20251228.png", "site": "defenseworld.net", "text": "Venus Concept Inc. (NASDAQ: VERO - Get Free Report) was the target of a large drop in short interest during the month of December. As of December 15th, there was short interest totaling 93,597 shares, a drop of 35.0% from the November 30th total of 144,013 shares. Based on an average daily trading volume, of 645,091", "url": "https://www.defenseworld.net/2025/12/28/venus-concept-inc-nasdaqvero-short-interest-down-35-0-in-december.html"}, {"symbol": "VERO", "publishedDate": "2025-12-28 02:14:53", "publisher": "Defense World", "title": "Sensus Healthcare (NASDAQ:SRTS) vs. Venus Concept (NASDAQ:VERO) Head-To-Head Comparison", "image": "https://images.financialmodelingprep.com/news/sensus-healthcare-nasdaqsrts-vs-venus-concept-nasdaqvero-headtohead-comparison-20251228.png", "site": "defenseworld.net", "text": "Sensus Healthcare (NASDAQ: SRTS - Get Free Report) and Venus Concept (NASDAQ: VERO - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings. Analyst Recommendations This is a summary of", "url": "https://www.defenseworld.net/2025/12/28/sensus-healthcare-nasdaqsrts-vs-venus-concept-nasdaqvero-head-to-head-comparison.html"}, {"symbol": "JFBR", "publishedDate": "2025-12-26 12:23:01", "publisher": "Benzinga", "title": "Jeffs' Brands Monetizes Fort Tech Stake To Fund Homeland Security Push", "image": "https://images.financialmodelingprep.com/news/jeffs-brands-monetizes-fort-tech-stake-to-fund-homeland-20251226.jpeg", "site": "feeds.benzinga.com", "text": "Jeffs' Brands (JFBR) shares fall after partial sale of Fort Technology stake. Company shifts focus to homeland security and tech initiatives.", "url": "https://www.benzinga.com/trading-ideas/movers/25/12/49596392/jeffs-brands-monetizes-fort-tech-stake-to-fund-homeland-security-push"}, {"symbol": "JFBR", "publishedDate": "2025-12-26 07:42:00", "publisher": "GlobeNewsWire", "title": "Jeffs' Brands to Sell Approximately 7% of Fort Technology's Outstanding Shares Reflecting up to CAD $20 million Valuation for Fort Technology", "image": "https://images.financialmodelingprep.com/news/jeffs-brands-to-sell-approximately-7-of-fort-technologys-20251226.jpg", "site": "globenewswire.com", "text": "As part of its strategic shift, Company is divesting retail assets to focus on homeland security and advanced technologies", "url": "https://www.globenewswire.com/news-release/2025/12/26/3210522/0/en/Jeffs-Brands-to-Sell-Approximately-7-of-Fort-Technology-s-Outstanding-Shares-Reflecting-up-to-CAD-20-million-Valuation-for-Fort-Technology.html"}, {"symbol": "JAGX", "publishedDate": "2025-12-26 02:04:58", "publisher": "Defense World", "title": "Jaguar Animal Health, Inc. (NASDAQ:JAGX) Short Interest Update", "image": "https://images.financialmodelingprep.com/news/jaguar-animal-health-inc-nasdaqjagx-short-interest-update-20251226.png", "site": "defenseworld.net", "text": "Jaguar Animal Health, Inc. (NASDAQ: JAGX - Get Free Report) saw a significant increase in short interest during the month of December. As of December 15th, there was short interest totaling 245,697 shares, an increase of 227.7% from the November 30th total of 74,987 shares. Currently, 7.1% of the company's stock are sold short. Based on", "url": "https://www.defenseworld.net/2025/12/26/jaguar-animal-health-inc-nasdaqjagx-short-interest-update.html"}, {"symbol": "JFBR", "publishedDate": "2025-12-24 09:19:00", "publisher": "GlobeNewsWire", "title": "Jeffs' Brands and Scanary: The Radar Revolution That Could Transform the Homeland-Security Market", "image": "https://images.financialmodelingprep.com/news/jeffs-brands-and-scanary-the-radar-revolution-that-could-20251224.jpg", "site": "globenewswire.com", "text": "Tel Aviv, Israel, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd. (Nasdaq: JFBR) (\u201cJeffs' Brands\u201d), \u00a0a data-driven e-commerce company strategically pivoting into homeland security, today provided additional information regarding Scanary Ltd. (\u201cScanary\u201d), an Israeli deep-tech startup's groundbreaking AI-powered radar system that promises to redefine concealed threat detection without disrupting the flow of people. In an era of emerging security threats-from mass shootings to terrorist attacks in crowded public spaces\u2014traditional security screening methods are increasingly inadequate. Long lines at metal detectors and X-ray machines create bottlenecks, frustrate crowds, and leave vulnerabilities in open areas where threats can enter undetected. Enter Scanary Ltd. (\u201cScanary\u201d), an Israeli deep-tech startup's groundbreaking AI-powered radar system that promises to redefine concealed threat detection without disrupting the flow of people.", "url": "https://www.globenewswire.com/news-release/2025/12/24/3210334/0/en/Jeffs-Brands-and-Scanary-The-Radar-Revolution-That-Could-Transform-the-Homeland-Security-Market.html"}, {"symbol": "TNMG", "publishedDate": "2025-12-24 06:30:00", "publisher": "PRNewsWire", "title": "TNL Mediagene Granted Continued Listing by Nasdaq Hearings Panel, Subject to Meeting $1 Bid Price Rule On or Before January 7, 2026", "image": "https://images.financialmodelingprep.com/news/tnl-mediagene-granted-continued-listing-by-nasdaq-hearings-panel-20251224.jpg", "site": "prnewswire.com", "text": "TOKYO and TAIPEI, Taiwan , Dec. 24, 2025 /PRNewswire/ -- TNL Mediagene (Nasdaq: TNMG) (the \"Company\"), a Tokyo-based next-generation digital media and data group in Asia, today announced that on December 23, 2025, the Company has been notified by the\u00a0Nasdaq Hearings Panel (the \"Panel\") of The Nasdaq Stock Market LLC (\"Nasdaq\") that the Company's request for continued listing on The Nasdaq Capital Market has been granted, subject to the following: On or before January 7, 2026, the Company must demonstrate compliance with the Listing Rule 5550(a)(2), or the $1 Bid Price Rule. It is a requirement during the exception period that the Company provide prompt notification of any significant events that occur during this time that may affect the Company's compliance with Nasdaq requirements.", "url": "https://www.prnewswire.com/news-releases/tnl-mediagene-granted-continued-listing-by-nasdaq-hearings-panel-subject-to-meeting-1-bid-price-rule-on-or-before-january-7-2026-302649221.html"}, {"symbol": "TNMG", "publishedDate": "2025-12-23 07:00:00", "publisher": "PRNewsWire", "title": "TNL Mediagene to Launch Agentic Newsroom, an AI-Driven Global Content System, and CiteRadar, an SaaS Analytics Platform for Monitoring AI Visibility", "image": "https://images.financialmodelingprep.com/news/tnl-mediagene-to-launch-agentic-newsroom-an-aidriven-global-20251223.jpg", "site": "prnewswire.com", "text": "-The Company announced the planned launch of two AI initiatives: the Agentic Newsroom and CiteRadar -Agentic Newsroom is an AI-driven content system that automates translation, localization and distribution of content across different markets in Asia -CiteRadar is an enterprise SaaS analytics platform that allows clients to monitor their AI visibility, including how AI models describe brands, products and competitive landscapes, in order to help clients control their narrative and brand consistency -Through these new tools, the Company is not only using AI to optimize internal operations, but also creating new B2B revenue opportunities TOKYO and TAIPEI , Dec. 23, 2025 /PRNewswire/ -- TNL Mediagene (Nasdaq: TNMG) (the \"Company\"), a Tokyo-based next-generation digital media and data group in Asia, today announced the planned launch of the Agentic Newsroom, an AI-driven global content system that automates translation, localization and distribution of content across international markets, and CiteRadar, an enterprise SaaS analytics platform that monitors how AI models describe brands, products and competitive landscapes to control for narrative and brand consistency. Agentic Newsroom: Autonomous AI-Driven Global Content Distribution Building on the Company's existing content synchronization capabilities, the Company will launch the Agentic Newsroom\u2014an AI-driven content system that automates translation, localization and distribution of content across different markets in Asia.", "url": "https://www.prnewswire.com/news-releases/tnl-mediagene-to-launch-agentic-newsroom-an-ai-driven-global-content-system-and-citeradar-an-saas-analytics-platform-for-monitoring-ai-visibility-302648699.html"}, {"symbol": "JFBR", "publishedDate": "2025-12-23 06:55:00", "publisher": "GlobeNewsWire", "title": "Jeffs' Brands Announces Corporate Rebranding: From Marketplace to Tech Powerhouse", "image": "https://images.financialmodelingprep.com/news/jeffs-brands-announces-corporate-rebranding-from-marketplace-to-tech-20251223.jpg", "site": "globenewswire.com", "text": "Company plans to shift its strategic focus from e-commerce to homeland security and advanced technologies Proposed pending name change to Nexera Technologies Ltd to reflect its future strategic focus Tel Aviv, Israel, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd (\u201cJeffs' Brands\u201d or the \u201cCompany\u201d) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, today announced a corporate rebranding to reflect its intended strategic focus on homeland security and advanced technologies. At the heart of this rebranding is the intention to change the Company's name to \u201cNexera Technologies Ltd\u201d, subject to the receipt of the necessary approvals.", "url": "https://www.globenewswire.com/news-release/2025/12/23/3209774/0/en/Jeffs-Brands-Announces-Corporate-Rebranding-From-Marketplace-to-Tech-Powerhouse.html"}, {"symbol": "IBRX", "publishedDate": "2025-12-23 01:14:57", "publisher": "Defense World", "title": "Reviewing HCW Biologics (NASDAQ:HCWB) and ImmunityBio (NASDAQ:IBRX)", "image": "https://images.financialmodelingprep.com/news/reviewing-hcw-biologics-nasdaqhcwb-and-immunitybio-nasdaqibrx-20251223.png", "site": "defenseworld.net", "text": "HCW Biologics (NASDAQ: HCWB - Get Free Report) and ImmunityBio (NASDAQ: IBRX - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation. Valuation and Earnings This table compares HCW Biologics and", "url": "https://www.defenseworld.net/2025/12/23/reviewing-hcw-biologics-nasdaqhcwb-and-immunitybio-nasdaqibrx.html"}, {"symbol": "TNMG", "publishedDate": "2025-12-22 07:00:00", "publisher": "PRNewsWire", "title": "TNL Mediagene Announces Early Success in AI Content Licensing Revenue Model via TollBit Marketplace Integration and Strategic Partnership", "image": "https://images.financialmodelingprep.com/news/tnl-mediagene-announces-early-success-in-ai-content-licensing-20251222.jpg", "site": "prnewswire.com", "text": "-The Company is the first media company in Japan to have integrated 15 of its media brands onto the TollBit platform to monetize AI-driven traffic across its media properties -TollBit is a platform that enables websites to monetize and protect their content from AI web scraping by acting as a digital \"tollbooth\" for AI agents and bots, allowing content owners to set rules, charge for access to their data and monitor AI activity -The TollBit platform provides a transparent and scalable mechanism for content monetization beyond traditional advertising and subscription models in the AI era and is considered the next frontier in content monetization -The Company has begun generating initial revenue from AI buyers through the integration with the TollBit platform, validating AI content licensing as a viable commercial model for premium digital media TOKYO and TAIPEI , Dec. 22, 2025 /PRNewswire/ --\u00a0TNL Mediagene (Nasdaq: TNMG) (the \"Company\"), a Tokyo-based next-generation digital media and data group in Asia, today announced that it has begun generating revenue through its integration with TollBit's AI licensing marketplace, marking an early validation of AI content licensing as a viable commercial model for premium digital media. TollBit is the leading platform helping publishers and creators monitor, manage, and monetize AI usage of their content.", "url": "https://www.prnewswire.com/news-releases/tnl-mediagene-announces-early-success-in-ai-content-licensing-revenue-model-via-tollbit-marketplace-integration-and-strategic-partnership-302647966.html"}, {"symbol": "TNMG", "publishedDate": "2025-12-19 07:30:00", "publisher": "PRNewsWire", "title": "TNL Mediagene Issues Shareholder Letter Providing H2 and 2025 Corporate Update", "image": "https://images.financialmodelingprep.com/news/tnl-mediagene-issues-shareholder-letter-providing-h2-and-2025-20251219.jpg", "site": "prnewswire.com", "text": "TOKYO and TAIPEI , Dec. 19, 2025 /PRNewswire/ -- TNL\u00a0Mediagene (Nasdaq: TNMG) (the \"Company\"), a Tokyo-based next-generation digital media and data group in Asia, today issued a letter to shareholders\u00a0from Joey Chung, Co-Founder and CEO, and Motoko Imada, Co-Founder and President of TNL Mediagene, discussing key recent positive and notable developments, milestones and achievements of the Company year-to-date in 2025 and plans for the year ahead. FY2025 summary performance guidance of $49.1 million Revenue, $17.8 million Gross Profit and $0.8 million Management Adjusted EBITDA Performance highlights strength in our Technology and Digital Studio business units offset by pressure in our Media & Branded Content business unit as a result of industry-wide AI\u00a0SEO shifts, stable Gross Profit margin and expanding Management Adjusted EBITDA margin driven by cost reduction initiatives Key capital structure milestones and new capital raised include repayment of our $4.7 million outstanding convertible note balance, $2.15 million in common equity and $375,000 in convertible notes raised from existing shareholders and new private investors, $1.5 million through a new convertible note from 3i at improved terms including 18-month maturity and 6-month interest and amortization holiday, and amendments to our existing outstanding\u00a0ELOC agreement with Tumin Stone with improved terms to allow for more efficient and lower-cost strategic use of this instrument at our sole discretion Several significant new strategic partnerships signed in the year including\u00a0CMoney, Taiwan's largest stock information and financial education platform serving over 10 million active users each month; PChome, one of Asia's largest e-commerce platforms similar to an Amazon; and Geniee to expand access to advertising creative solution \"Cr.ED\", a data-powered creative platform and SaaS service that helps marketers create rich and engaging interactive digital advertisements more efficiently, among others Large and active investor conference and event hosting calendar with some key wins including\u00a0TechGALA Japan 2025 and appointment as Lead Partner for TechGALA Japan 2026; hosting 2025 Becoming Aces Awards and Launch of \"Rising Star in Digital Impact\" with 91APP Foundation; hosting INSIDE Future Day 2025 \"Next-Gen AI Agents: Building a New Era of Human-AI Collaboration\"; and co-hosting 2025 Generative AI Conference Several key initiatives were launched in the year to better position the Company competitively on a revenue and cost and basis including continued diversification into Technology, Digital Studio and new media verticals; expanding proven successful media properties into new language markets with our\u00a0multilingualization strategy; hiring and promoting key C-level and editorial talent; and continued strong progress on staff restructuring and reorganization efforts that we expect to bring significant cost savings Dear Shareholders, As we conclude 2025, we want to give an update on some notable developments at the Company as well as look back at key milestones achieved throughout this transformative year, and we will also highlight some of our plans for the year ahead.", "url": "https://www.prnewswire.com/news-releases/tnl-mediagene-issues-shareholder-letter-providing-h2-and-2025-corporate-update-302646817.html"}, {"symbol": "TNMG", "publishedDate": "2025-12-19 06:30:00", "publisher": "PRNewsWire", "title": "TNL Mediagene Announces 1-for-20 Share Consolidation", "image": "https://images.financialmodelingprep.com/news/tnl-mediagene-announces-1for20-share-consolidation-20251219.jpg", "site": "prnewswire.com", "text": "TOKYO and TAIPEI, Taiwan , Dec. 19, 2025 /PRNewswire/ -- TNL Mediagene (Nasdaq: TNMG) (the \"Company\"), a Tokyo-based next-generation digital media and data group in Asia, today announced that it will implement a 1-for-20 share consolidation (also known as reverse stock split) of the Company's ordinary shares (the \"Share Consolidation\"). The Company's ordinary shares will continue to trade on The Nasdaq Capital Market under the existing ticker symbol \"TNMG\" and are expected to begin trading on a split-adjusted basis with a newly assigned CUSIP number of G8924F121 when the market opens on Tuesday, December 23, 2025.", "url": "https://www.prnewswire.com/news-releases/tnl-mediagene-announces-1-for-20-share-consolidation-302646810.html"}, {"symbol": "IBRX", "publishedDate": "2025-12-18 11:40:45", "publisher": "Zacks Investment Research", "title": "3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment", "image": "https://images.financialmodelingprep.com/news/3-cancer-stocks-to-buy-amid-rapid-advances-in-20251218.jpg", "site": "zacks.com", "text": "J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.", "url": "https://www.zacks.com/stock/news/2806268/3-cancer-stocks-to-buy-amid-rapid-advances-in-cancer-treatment?cid=CS-STOCKNEWSAPI-FT-cancer-2806268"}, {"symbol": "LCFY", "publishedDate": "2025-12-17 08:00:00", "publisher": "GlobeNewsWire", "title": "Locafy Reports Continued Commercial Growth as Localizer Adoption and Partner Results Build into CY 2026", "image": "https://images.financialmodelingprep.com/news/locafy-reports-continued-commercial-growth-as-localizer-adoption-and-20251217.jpg", "site": "globenewswire.com", "text": "An approximately $24,000 net increase in monthly subscription sales to date since November 2025 Localizer adoption expands to 145 independent State Farm agencies, with additional sales growth outside State Farm agents Partner campaigns are also now delivering measurable results in the home services sector, driving further sales growth PERTH, Australia, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Locafy Limited (Nasdaq: LCFY, LCFYW) (\u201cLocafy\u201d or the \u201cCompany\u201d), a global software-as-a-service technology company specializing in location-based digital marketing solutions, including AI-powered search engine optimization (AI SEO), today provided a commercial update highlighting continued subscription growth, expanding U.S. adoption of its Localizer\u2122 platform, and accelerating partner-led performance following its November 2025 momentum update. \u201cSince our November commercial update, we've continued to see steady growth in subscription revenue and strong demand for Localizer and Localizer SAB across the U.S. market,\u201d said Gavin Burnett, CEO of Locafy.", "url": "https://www.globenewswire.com/news-release/2025/12/17/3206925/0/en/Locafy-Reports-Continued-Commercial-Growth-as-Localizer-Adoption-and-Partner-Results-Build-into-CY-2026.html"}, {"symbol": "JFBR", "publishedDate": "2025-12-17 07:42:00", "publisher": "GlobeNewsWire", "title": "Jeffs' Brands: KeepZone AI Successfully Completes Live Pilot Demonstrating Checkpoint-Free Weapon Screening at High-Profile Event", "image": "https://images.financialmodelingprep.com/news/jeffs-brands-keepzone-ai-successfully-completes-live-pilot-demonstrating-20251217.jpg", "site": "globenewswire.com", "text": "Tel Aviv, Israel, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd (\u201cJeffs' Brands\u201d or the \u201cCompany\u201d) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, which recently began expanding into the global homeland security sector through advanced AI-driven solutions, today announced that its wholly owned subsidiary, KeepZone AI Inc. (\u201cKeepZone\u201d), has successfully completed a live operational security technology pilot of\u00a0Scanary Ltd.'s (\u201cScanary\u201d) next-generation concealed weapon detection system (the \u201cSystem\u201d), at Pais Arena Jerusalem (the \u201cArena\u201d) during a high-profile concert event held on December 10 and 11, 2025.", "url": "https://www.globenewswire.com/news-release/2025/12/17/3206910/0/en/Jeffs-Brands-KeepZone-AI-Successfully-Completes-Live-Pilot-Demonstrating-Checkpoint-Free-Weapon-Screening-at-High-Profile-Event.html"}, {"symbol": "IBRX", "publishedDate": "2025-12-16 09:00:00", "publisher": "Business Wire", "title": "ANKTIVA\u00ae with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer", "image": "https://images.financialmodelingprep.com/news/anktiva-with-bcg-demonstrates-96-survival-from-bladder-cancer-20251216.jpg", "site": "businesswire.com", "text": "CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA\u00ae (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Gu\u00e9rin (BCG) demonstrates efficacy at 12 and 36 months, including disease-free survival (DFS), disease-specific survival (DSS), long-term progression-free survival (PFS), and high cystectomy avoidance in patients with BCG-unresponsive high-grade papillary-only non-muscle invasive bladder cancer.", "url": "https://www.businesswire.com/news/home/20251216185945/en/ANKTIVA%C2%AE-with-BCG-Demonstrates-96-Survival-from-Bladder-Cancer-at-Three-Years-with-Median-Survival-Not-Yet-Reached-in-BCG-Unresponsive-High-Grade-Papillary-Only-Non-Muscle-Invasive-Bladder-Cancer/"}, {"symbol": "JFBR", "publishedDate": "2025-12-16 06:58:00", "publisher": "GlobeNewsWire", "title": "Jeffs' Brands Strengthens Strategic Partnership with Scanary Through Expanded Distribution Agreements Covering Key Global Territories and Israeli Stadiums", "image": "https://images.financialmodelingprep.com/news/jeffs-brands-strengthens-strategic-partnership-with-scanary-through-expanded-distribution-20251216.jpg", "site": "globenewswire.com", "text": "KeepZone AI is expected to complete full $1 million consideration payment schedule on track, with first installment already executed", "url": "https://www.globenewswire.com/news-release/2025/12/16/3206073/0/en/Jeffs-Brands-Strengthens-Strategic-Partnership-with-Scanary-Through-Expanded-Distribution-Agreements-Covering-Key-Global-Territories-and-Israeli-Stadiums.html"}, {"symbol": "JFBR", "publishedDate": "2025-12-16 04:03:05", "publisher": "Defense World", "title": "Jeffs\u2019 Brands (NASDAQ:JFBR) Trading Down 5.1%  \u2013 Should You Sell?", "image": "https://images.financialmodelingprep.com/news/jeffs-brands-nasdaqjfbr-trading-down-51-should-you-sell-20251216.jpg", "site": "defenseworld.net", "text": "Jeffs' Brands Ltd. (NASDAQ: JFBR - Get Free Report) shares traded down 5.1% during mid-day trading on Monday. The company traded as low as $1.04 and last traded at $1.11. 2,428,932 shares were traded during trading, a decline of 20% from the average session volume of 3,021,228 shares. The stock had previously closed at $1.17.", "url": "https://www.defenseworld.net/2025/12/16/jeffs-brands-nasdaqjfbr-trading-down-5-1-should-you-sell.html"}, {"symbol": "JAGX", "publishedDate": "2025-12-15 09:00:00", "publisher": "Accesswire", "title": "Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)", "image": "https://images.financialmodelingprep.com/news/jaguar-health-announces-abstract-submission-for-preliminary-data-from-20251215.jpg", "site": "accessnewswire.com", "text": "SBS-IF is the second orphan disease target indication for Jaguar's intestinal failure program, which includes microvillus inclusion disease (MVID) - for which the company completed a meeting in October 2025 with the FDA in support of a possible expedited approval pathway SAN FRANCISCO, CA / ACCESS Newswire / December 15, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Jaguar family company Napo Pharmaceuticals' (Napo's) independent investigator at a leading SBS-IF treatment institution submitted an abstract describing preliminary findings from a clinical trial evaluating a novel oral liquid formulation of crofelemer in adult SBS-IF patients. This abstract is for consideration for presentation at the May 2-5, 2026 Digestive Disease Week\u00ae conference.", "url": "https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-announces-abstract-submission-for-preliminary-data-from-1117305"}, {"symbol": "JFBR", "publishedDate": "2025-12-15 08:18:00", "publisher": "GlobeNewsWire", "title": "Jeffs' Brands: KeepZone AI Signs Exclusive Distribution Agreement, Expanding Homeland Security Portfolio", "image": "https://images.financialmodelingprep.com/news/jeffs-brands-keepzone-ai-signs-exclusive-distribution-agreement-expanding-homeland-20251215.jpg", "site": "globenewswire.com", "text": "Tel Aviv, Israel, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd (\u201cJeffs' Brands\u201d or the \u201cCompany\u201d) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, which recently began expanding into the global homeland security sector through advanced AI-driven solutions, today announced that its wholly owned subsidiary, KeepZone AI Inc., (\u201cKeepZone\u201d), has signed an exclusive distribution agreement with Zorronet Ltd. (\u201dZorronet\u201d), an innovative Israeli deep-tech company specializing in autonomous AI-driven security platform, which is a subsidiary of Water.io,and is majority-owned by Star 26 Capital Inc., which is subject to a pending acquisition by Nukkleus Inc. (Nasdaq: NUKK).", "url": "https://www.globenewswire.com/news-release/2025/12/15/3205410/0/en/Jeffs-Brands-KeepZone-AI-Signs-Exclusive-Distribution-Agreement-Expanding-Homeland-Security-Portfolio.html"}, {"symbol": "TNMG", "publishedDate": "2025-12-15 07:00:00", "publisher": "PRNewsWire", "title": "Sidoti Highlights Improved Financial Flexibility, Shelf Eligibility, Reduced Stock Overhang, and Focus on Operational Execution at TNL Mediagene", "image": "https://images.financialmodelingprep.com/news/sidoti-highlights-improved-financial-flexibility-shelf-eligibility-reduced-stock-20251215.jpg", "site": "prnewswire.com", "text": "TOKYO , Dec. 15, 2025 /PRNewswire/ -- TNL Mediagene (Nasdaq: TNMG) (the \"Company\"), a Tokyo-based next-generation digital media and data group in Asia, today announced that Sidoti & Company, LLC (\"Sidoti\") has published an update note highlighting improved financial flexibility and focus on operational execution at the Company. \"We view 2026 as a transition year for TNL Mediagene, with attention shifting from capital structure actions to operating execution following the resolution of prior SPAC-related issues.", "url": "https://www.prnewswire.com/news-releases/sidoti-highlights-improved-financial-flexibility-shelf-eligibility-reduced-stock-overhang-and-focus-on-operational-execution-at-tnl-mediagene-302642190.html"}, {"symbol": "IBRX", "publishedDate": "2025-12-12 12:00:51", "publisher": "Benzinga", "title": "ImmunityBio Moves Closer To EU Approval For Bladder Cancer Therapy", "image": "https://images.financialmodelingprep.com/news/immunitybio-moves-closer-to-eu-approval-for-bladder-cancer-20251212.jpg", "site": "benzinga.com", "text": "The European Medicines Agency has recommended granting a conditional marketing authorization for ImmunityBio, Inc.\u2018s (NASDAQ: IBRX) Anktiva (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Gu\u00e9rin (BCG) for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ.", "url": "https://www.benzinga.com/news/health-care/25/12/49367624/immunitybio-moves-closer-to-eu-approval-for-bladder-cancer-therapy"}, {"symbol": "IBRX", "publishedDate": "2025-12-12 06:10:00", "publisher": "Business Wire", "title": "ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA\u00ae with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ\u2014A First in Europe", "image": "https://images.financialmodelingprep.com/news/immunitybio-receives-conditional-marketing-authorization-recommendation-from-the-european-20251212.jpg", "site": "businesswire.com", "text": "CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a leading immunotherapy company, announced today that the European Medicines Agency has recommended granting a conditional marketing authorization in the EU for ANKTIVA\u00ae (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Gu\u00e9rin (BCG) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ. This recommendation will help facilitate early access to medicines that address c.", "url": "https://www.businesswire.com/news/home/20251212117157/en/ImmunityBio-Receives-Conditional-Marketing-Authorization-Recommendation-from-the-European-Medicines-Agency-for-ANKTIVA%C2%AE-with-BCG-for-Non-Muscle-Invasive-Bladder-Cancer-Carcinoma-in-Situ%E2%80%94A-First-in-Europe/"}, {"symbol": "TNMG", "publishedDate": "2025-12-11 07:00:00", "publisher": "PRNewsWire", "title": "TNL Mediagene Partners with CMoney, Taiwan's Leading Financial Platform with 10 Million Users, to Redefine the AdTech Landscape in Taiwan", "image": "https://images.financialmodelingprep.com/news/tnl-mediagene-partners-with-cmoney-taiwans-leading-financial-platform-20251211.jpg", "site": "prnewswire.com", "text": "The Company and Taiwan's leading financial data company\u00a0CMoney announced a strategic partnership to combine retail data and AI advertising technologies\u00a0 CMoney's anonymized retail data will be integrated into Ad2iction's Ad2 AI Agent solution to strengthen audience insights and campaign precision The strategic partnership expands the Company's\u00a0AdTech development roadmap by building a retail media network (RMN) data ecosystem that links online interests with offline purchase behavior Both companies aim to advance data empowerment and AI-driven marketing innovation across Taiwan's media and advertising technology industries TAIPEI , Dec. 11, 2025 /PRNewswire/ -- TNL\u00a0Mediagene (Nasdaq: TNMG) (the \"Company\"), a Tokyo-based next-generation digital media and data group in Asia, today announced a strategic partnership with CMoney to integrate CMoney's retail data assets into its subsidiary Ad2iction's Ad2 Network and AI-powered Ad2 AI Audience(AIA) solution, combining their respective strengths in media content and retail data to deepen audience insights in Taiwan and empower brand advertisers with more data-driven marketing decisions. CMoney is Taiwan's largest stock information and financial education platform, serving over 10 million active users each month.", "url": "https://www.prnewswire.com/news-releases/tnl-mediagene-partners-with-cmoney-taiwans-leading-financial-platform-with-10-million-users-to-redefine-the-adtech-landscape-in-taiwan-302639067.html"}, {"symbol": "JAGX", "publishedDate": "2025-12-10 09:00:00", "publisher": "Accesswire", "title": "FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs", "image": "https://images.financialmodelingprep.com/news/fda-approves-renewal-of-canaleviaca1-jaguar-healths-drug-for-20251210.jpg", "site": "accessnewswire.com", "text": "Conditional approval extended through December 2026 for the treatment of CID in dogs CID confirmatory effectiveness trial expected to conclude in February 2026, ahead of FDA's June deadline - 51 dogs enrolled to date; ~49 more expected SAN FRANCISCO, CA / ACCESS Newswire / December 10, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the U.S. Food and Drug Administration (FDA) has granted renewal of the conditional approval for Canalevia-CA1 (crofelemer delayed-release tablets). Canalevia-CA1, the company's prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs, is available from multiple leading veterinary distributors in the U.S., including Chewy.", "url": "https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/fda-approves-renewal-of-canalevia-ca1-jaguar-healths-drug-for-chemoth-1116220"}, {"symbol": "JFBR", "publishedDate": "2025-12-10 08:32:00", "publisher": "GlobeNewsWire", "title": "Jeffs' Brands: KeepZone Announces the Expansion of Scanary Distribution Agreement to Include Exclusive Rights for Stadiums in Israel", "image": "https://images.financialmodelingprep.com/news/jeffs-brands-keepzone-announces-the-expansion-of-scanary-distribution-20251210.jpg", "site": "globenewswire.com", "text": "KeepZone will complete the first i nstallment payment of $200,000 under the Scanary distribution agreement by December 11, 2025", "url": "https://www.globenewswire.com/news-release/2025/12/10/3203167/0/en/Jeffs-Brands-KeepZone-Announces-the-Expansion-of-Scanary-Distribution-Agreement-to-Include-Exclusive-Rights-for-Stadiums-in-Israel.html"}, {"symbol": "PRFX", "publishedDate": "2025-12-10 08:30:00", "publisher": "GlobeNewsWire", "title": "PainReform Confirms the Ability of Its LayerBio Drop-Less Sustained-Release Ocular Platform to Accommodate Multiple Drug Entities", "image": "https://images.financialmodelingprep.com/news/painreform-confirms-the-ability-of-its-layerbio-dropless-sustainedrelease-20251210.jpg", "site": "globenewswire.com", "text": "TEL AVIV, Israel, Dec. 10, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) today announced that its pharmaceutical division has completed an R&D assessment of LayerBio's proprietary drop-less, sustained-release ocular drug-delivery platform.", "url": "https://www.globenewswire.com/news-release/2025/12/10/3203166/0/en/PainReform-Confirms-the-Ability-of-Its-LayerBio-Drop-Less-Sustained-Release-Ocular-Platform-to-Accommodate-Multiple-Drug-Entities.html"}, {"symbol": "JAGX", "publishedDate": "2025-12-09 08:10:01", "publisher": "Globe News Wire", "title": "Presenting on Emerging Growth Conference 88 Day 1 on December 10; Register to live stream", "image": "https://images.financialmodelingprep.com/news/presenting-on-emerging-growth-conference-88-day-1-on-december-20251209.png", "site": "globenewswire.com", "text": "MIAMI, Dec. 09, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth. com a leading independent small cap media portal announces the schedule of the 88th Emerging Growth Conference on December 10 and 11, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products and services, focused strategy, execution, and the overall potential for long-term growth.", "url": "https://www.globenewswire.com/news-release/2025/12/09/3202218/0/en/Presenting-on-Emerging-Growth-Conference-88-Day-1-on-December-10-Register-to-live-stream.html"}, {"symbol": "TNMG", "publishedDate": "2025-12-09 08:00:00", "publisher": "PRNewsWire", "title": "TNL Mediagene Announces Successful INSIDE Future Day 2025 and Releases New AI Agent Industry White Paper", "image": "https://images.financialmodelingprep.com/news/tnl-mediagene-announces-successful-inside-future-day-2025-and-releases-20251209.jpg", "site": "prnewswire.com", "text": "The Company successfully hosted INSIDE Future Day 2025 in Taipei on December 9 th INSIDE Future Day is a forum event organized by the Company's INSIDE media property and has been the Company's flagship technology event since 2019. The event focuses on emerging trends in technology and innovation, bringing together key figures from the tech industry; including entrepreneurs, investors and senior executives; to share their insights and experiences on future technologies, industry shifts and startup trends During the forum, the Company's technology media brand INSIDE released a new industry white paper titled \"AI Agent Era: Enterprise Adoption in Taiwan and Future Challenges\" based on interviews with more than 20 AI Agent solution providers as well as survey responses from over 150 enterprise decision makers This year's forum attracted more than 400 registrations, reflecting broad interest from participants across technology and business sectors The initiative reflects the Company's continued effort to provide research and knowledge resources that support industry stakeholders TAIPEI , Dec. 9, 2025 /PRNewswire/ -- TNL Mediagene (Nasdaq: TNMG) (the \"Company\"), a Tokyo-based next-generation digital media and data group in Asia, today announced that it successfully hosted INSIDE Future Day 2025 in Taipei, attracting over 400 registrations, and released its latest AI Agent industry white paper to provide industry stakeholders with a clearer view of developments related to next-generation AI Agents and their potential implications for enterprise operations.", "url": "https://www.prnewswire.com/news-releases/tnl-mediagene-announces-successful-inside-future-day-2025-and-releases-new-ai-agent-industry-white-paper-302636577.html"}, {"symbol": "JAGX", "publishedDate": "2025-12-08 16:15:00", "publisher": "Accesswire", "title": "Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders", "image": "https://images.financialmodelingprep.com/news/jaguar-health-reports-approval-of-all-proposals-at-december-20251208.jpg", "site": "accessnewswire.com", "text": "Jaguar CEO Lisa Conte presenting December 10 from 3:25pm - 3:35pm Eastern at the Emerging Growth Conference to provide updates on near-term catalysts; Click here to register Initial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure due to microvillus inclusion disease (MVID), reducing the volume of the total parenteral support (PS) necessary for them to survive, though with associated toxicity; Groundbreaking PS reduction of up to 37%; No approved treatments exist for MVID Company completed meeting with FDA October 2, 2025 for advice on advancing its ongoing placebo-controlled trial of crofelemer in support of possible expedited approval pathway for crofelemer for treatment of MVID SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 8, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\" or the \"Company\") today announced the voting results of the Company's Special Meeting of Stockholders held on December 8, 2025 (the \"Special Meeting\"). Three proposals were submitted to and approved by the stockholders of the Company at the Special Meeting.", "url": "https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-reports-approval-of-all-proposals-at-december-2025-spec-1115563"}, {"symbol": "JFBR", "publishedDate": "2025-12-08 09:10:00", "publisher": "GlobeNewsWire", "title": "Jeffs' Brands Appoints Security Executive Alon Dayan as CEO of KeepZone AI Inc., Strengthening Leadership in Global Homeland Security Expansion", "image": "https://images.financialmodelingprep.com/news/jeffs-brands-appoints-security-executive-alon-dayan-as-ceo-20251208.jpg", "site": "globenewswire.com", "text": "Tel Aviv, Israel, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd (\u201cJeffs' Brands\u201d or the \u201cCompany\u201d) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, today announced the appointment of Alon Dayan as Chief Executive Officer (\u201cCEO\u201d) of its wholly-owned subsidiary, KeepZone AI Inc., formerly known as Jeffs' Brands Holdings Inc. (\u201cKeepZone\u201d). This strategic appointment comes on the heels of KeepZone's recent entry into the global homeland security market through a definitive distribution agreement with Scanary Ltd. (\u201cScanary\u201d), positioning the Company to capitalize on the surging demand for advanced AI-driven threat detection technologies.", "url": "https://www.globenewswire.com/news-release/2025/12/08/3201598/0/en/Jeffs-Brands-Appoints-Security-Executive-Alon-Dayan-as-CEO-of-KeepZone-AI-Inc-Strengthening-Leadership-in-Global-Homeland-Security-Expansion.html"}, {"symbol": "JFBR", "publishedDate": "2025-12-05 08:32:00", "publisher": "GlobeNewsWire", "title": "Jeffs' Brands Enters into a Definitive Agreement with Scanary, Marking Entry into the Global Homeland Security Market", "image": "https://images.financialmodelingprep.com/news/jeffs-brands-enters-into-a-definitive-agreement-with-scanary-20251205.jpg", "site": "globenewswire.com", "text": "Tel Aviv, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd (\u201cJeffs' Brands\u201d or the \u201cCompany\u201d) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, announced today that KeepZone AI Inc., its wholly owned subsidiary (\u201cKeepZone\u201d or the \u201cSubsidiary\u201d) has entered into a definitive distribution agreement (the \u201cAgreement\u201d) with Scanary Ltd. (\u201cScanary\u201d), an Israeli deep-tech developer of 3D imaging, electromagnetic, AI-powered threat detection systems. This transaction marks the Company's strategic entry into the fast-growing global homeland-security sector.", "url": "https://www.globenewswire.com/news-release/2025/12/05/3200710/0/en/Jeffs-Brands-Enters-into-a-Definitive-Agreement-with-Scanary-Marking-Entry-into-the-Global-Homeland-Security-Market.html"}, {"symbol": "IBRX", "publishedDate": "2025-12-03 05:00:25", "publisher": "Seeking Alpha", "title": "A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs", "image": "https://images.financialmodelingprep.com/news/a-second-anktiva-approval-could-be-the-catalyst-immunitybio-20251203.jpg", "site": "seekingalpha.com", "text": "ImmunityBio delivered strong 3Q25 results, with Anktiva driving 434% YoY product revenue growth and a narrowed operating loss. IBRX's cash position improved to $257.8 million, providing a 3-4 quarter runway, though net debt remains high at $603 million. The company's robust adoption underpins current valuation; future growth hinges on expanding indications and successful clinical trial readouts.", "url": "https://seekingalpha.com/article/4849684-a-second-anktiva-approval-could-be-the-catalyst-immunitybio-needs"}, {"symbol": "PRFX", "publishedDate": "2025-12-02 09:15:00", "publisher": "GlobeNewsWire", "title": "PainReform Commences Development for OcuRing\u2122-K Phase II Trial, LayerBio's Drop-Less Sustained-Release Ocular Therapy", "image": "https://images.financialmodelingprep.com/news/painreform-commences-development-for-ocuringk-phase-ii-trial-layerbios-20251202.jpg", "site": "globenewswire.com", "text": "Development plan positions OcuRing\u2122-K for advancement in the fast-growing, multi-billion-dollar global cataract surgery market Development plan positions OcuRing\u2122-K for advancement in the fast-growing, multi-billion-dollar global cataract surgery market", "url": "https://www.globenewswire.com/news-release/2025/12/02/3198088/0/en/PainReform-Commences-Development-for-OcuRing-K-Phase-II-Trial-LayerBio-s-Drop-Less-Sustained-Release-Ocular-Therapy.html"}, {"symbol": "JAGX", "publishedDate": "2025-12-02 09:00:00", "publisher": "Accesswire", "title": "Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study", "image": "https://images.financialmodelingprep.com/news/jaguar-health-makes-submission-to-ema-regarding-eu-approval-20251202.jpg", "site": "accessnewswire.com", "text": "Jaguar's requesting advice from EMA on EU approval pathway for general diarrhea of FDA conditionally approved Canalevia\u00ae A novel non-antibiotic approach to diarrhea treatment is important because there are no FDA-approved drugs to treat general diarrhea in dogs, the second most common reason for visits to veterinary emergency hospitals SAN FRANCISCO, CA / ACCESS Newswire / December 2, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar), today announced that its Italian subsidiary, Napo Therapeutics S.p.A., has submitted a request to the European Medicines Agency (EMA) to have the EMA's Committee for Veterinary Medicinal Products (CVMP) provide scientific advice regarding the company's plan to pursue approval of Canalevia (crofelemer delayed-release tablets) in the European Union for treatment of general diarrhea in dogs based on data from a study Jaguar completed in 200 dogs in 2017.", "url": "https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-makes-submission-to-ema-regarding-eu-approval-pathway-f-1113655"}, {"symbol": "TNMG", "publishedDate": "2025-12-02 07:00:00", "publisher": "PRNewsWire", "title": "TNL Mediagene Hosts 2025 Becoming Aces Awards and Launches \"Rising Star in Digital Impact\" with 91APP Foundation to Advance Youth Innovation and Sustainable Impact", "image": "https://images.financialmodelingprep.com/news/tnl-mediagene-hosts-2025-becoming-aces-awards-and-launches-20251202.jpg", "site": "prnewswire.com", "text": "- The Company's Becoming Aces hosted the 9th Becoming Aces Awards, recognizing 20 youth\u00a0changemakers across Taiwan - The inaugural \"Rising Star in Digital Impact\" award launched in collaboration with the 91APP Foundation - Honorees showcased digital innovation in women's empowerment, digital cultural engagement and local brand development - The initiative extends into the \"2025 Becoming Aces Running Program,\" led by Mario Yang, Co-Founder and Taiwan Chief Content Officer of the Company, inviting past Becoming Aces awardees to collectively train for the Taipei Marathon half-marathon - The Company continues to leverage its content network, AI capabilities and cross-sector partnerships to amplify youth-driven innovation and expand social impact across Asia TAIPEI , Dec. 2, 2025 /PRNewswire/ -- TNL Mediagene (Nasdaq: TNMG) (the \"Company\"), a Tokyo-based next-generation digital media and data group in Asia, today announced that its content platform Becoming Aces successfully hosted the 9th annual Becoming Aces Awards on November 8 in Taipei and launched the Rising Star in Digital Impact award in collaboration with the 91APP Foundation. Established in 2015, Becoming Aces aims to spotlight young leaders and amplify the public value of civic-driven innovation.", "url": "https://www.prnewswire.com/news-releases/tnl-mediagene-hosts-2025-becoming-aces-awards-and-launches-rising-star-in-digital-impact-with-91app-foundation-to-advance-youth-innovation-and-sustainable-impact-302630292.html"}, {"symbol": "JFBR", "publishedDate": "2025-12-01 07:32:00", "publisher": "GlobeNewsWire", "title": "Jeffs' Brands Plans to Enter the Homeland Security Market with a Unique Security AI Screening Technology", "image": "https://images.financialmodelingprep.com/news/jeffs-brands-plans-to-enter-the-homeland-security-market-20251201.jpg", "site": "globenewswire.com", "text": "Announces Exclusive Multi-Continent Distribution MOU for Revolutionary AI-Driven Electromagnetic Imaging Security System", "url": "https://www.globenewswire.com/news-release/2025/12/01/3196923/0/en/Jeffs-Brands-Plans-to-Enter-the-Homeland-Security-Market-with-a-Unique-Security-AI-Screening-Technology.html"}, {"symbol": "BIYA", "publishedDate": "2025-11-29 03:16:50", "publisher": "Defense World", "title": "Nextdoor (NYSE:KIND) vs. Baiya International Group (NASDAQ:BIYA) Head-To-Head Survey", "image": "https://images.financialmodelingprep.com/news/nextdoor-nysekind-vs-baiya-international-group-nasdaqbiya-headtohead-survey-20251129.png", "site": "defenseworld.net", "text": "Baiya International Group (NASDAQ: BIYA - Get Free Report) and Nextdoor (NYSE: KIND - Get Free Report) are both small-cap computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation and institutional ownership. Institutional and Insider Ownership 35.7%", "url": "https://www.defenseworld.net/2025/11/29/nextdoor-nysekind-vs-baiya-international-group-nasdaqbiya-head-to-head-survey.html"}, {"symbol": "TNMG", "publishedDate": "2025-11-25 07:00:00", "publisher": "PRNewsWire", "title": "TNL Mediagene Launches INSAIDA, New Video News Program Offering Deeper Analysis of Business and Society in Japan", "image": "https://images.financialmodelingprep.com/news/tnl-mediagene-launches-insaida-new-video-news-program-offering-deeper-20251125.jpg", "site": "prnewswire.com", "text": "-The Company today announced the launch of INSAIDA, a new video news program designed to deliver deeper visual analysis of business, economics and society -INSAIDA combines Business Insider Japan's editorial reporting with video-native storytelling to meet the growing demand for trustworthy, easy-to-understand news in video format -The program leverages Business Insider Japan's multi-angle coverage and editorial expertise to provide context-rich reporting for younger digital-native audiences -INSAIDA content will be distributed through Business Insider Japan's official YouTube channel from November 19, 2025 TOKYO , Nov. 25, 2025 /PRNewswire/ -- TNL Mediagene (Nasdaq: TNMG) (the \"Company\") today announced the official launch of INSAIDA by Business Insider Japan (\"INSAIDA\"), a new video news program that delivers visually driven, in-depth reporting on business, economics, international affairs and societal trends. The program is produced under the leadership of veteran broadcast journalist Toru Nakamaru, who was appointed Head of Video at Business Insider Japan in October 2025.", "url": "https://www.prnewswire.com/news-releases/tnl-mediagene-launches-insaida-new-video-news-program-offering-deeper-analysis-of-business-and-society-in-japan-302625458.html"}, {"symbol": "JAGX", "publishedDate": "2025-11-24 09:00:00", "publisher": "Accesswire", "title": "Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones", "image": "https://images.financialmodelingprep.com/news/jaguar-health-secures-new-patent-for-crofelemer-in-short-20251124.jpg", "site": "accessnewswire.com", "text": "This new IP supports crofelemer's global exclusivity in rare pediatric intestinal failure coincident with published clinical data showing reductions in parenteral support requirements with crofelemer - supporting Jaguar's strategy to secure non-dilutive partnership funding Recent publication by members of Jaguar's Scientific Advisory Board and other intestinal failure key opinion leaders: \"Targeted Literature Review and Assessment of Evidence in Microvillus Inclusion Disease (MVID)\" SAN FRANCISCO, CA / ACCESS Newswire / November 24, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that the Australian Patent Office has issued a new patent to Jaguar family company Napo Pharmaceuticals (Napo) for methods for treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, in patients with an inhibitor of chloride-ion transport such as crofelemer, Jaguar's novel plant-based prescription drug. \"This new patent expands the international IP protection supporting crofelemer's development in short bowel syndrome with intestinal failure (SBS-IF),\" said Lisa Conte, founder, president, and CEO.", "url": "https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-secures-new-patent-for-crofelemer-in-short-bowel-syndro-1106126"}, {"symbol": "TNMG", "publishedDate": "2025-11-24 07:00:00", "publisher": "PRNewsWire", "title": "TNL Mediagene Announces GIZMART's Debut Project Keychron Nape Pro Hits \u00a5100 million in GMV in 12 Hours, Validating New Digital Media-Commerce Strategy", "image": "https://images.financialmodelingprep.com/news/tnl-mediagene-announces-gizmarts-debut-project-keychron-nape-pro-20251124.jpg", "site": "prnewswire.com", "text": "-On November 20, the Company launched GIZMART, a new digital media-commerce initiative that positions the Company's media brand Gizmodo Japan as a co-developer of hardware and creator-focused products -The Company launched a crowdfunding campaign for the \"Keychron Nape Pro\" trackball device, jointly developed with the global keyboard brand \"Keychron\", as the first project under this initiative -The \"Keychron Nape Pro\" crowdfunding campaign surpassed \u00a5100 million in GMV within 12 hours, marking the beginning of the Company's product development and commerce strategy aimed at expanding within Japan TOKYO , Nov. 24, 2025 /PRNewswire/ -- TNL Mediagene (Nasdaq: TNMG) (the \"Company\"), a Tokyo-based next-generation digital media and data group in Asia, today announced that its curated e-commerce platform GIZMART generated over \u00a5100 million in gross merchandise value (\"GMV\") within just 12\u00a0hours of launching its debut crowdfunding campaign for the Keychron Nape Pro trackball device. The Company launched the GIZMART crowdfunding campaign via a live stream on Gizmodo Japan's YouTube channel, drawing over 1,800 concurrent viewers.", "url": "https://www.prnewswire.com/news-releases/tnl-mediagene-announces-gizmarts-debut-project-keychron-nape-pro-hits-100-million-in-gmv-in-12-hours-validating-new-digital-media-commerce-strategy-302624430.html"}, {"symbol": "JAGX", "publishedDate": "2025-11-20 09:00:00", "publisher": "Accesswire", "title": "In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial", "image": "https://images.financialmodelingprep.com/news/in-support-of-possible-expedited-approval-pathway-for-crofelemer-20251120.jpg", "site": "accessnewswire.com", "text": "Crofelemer can potentially extend lives of MVID patients - infants and children who face the lethal natural history of the disease Parenteral support reduction of up to 37% is groundbreaking; No approved treatments exist for MVID in any region SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 20, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that, in support of a possible expedited approval pathway for crofelemer for treatment of intestinal failure in patients with the ultrarare genetic disorder microvillus inclusion disease (MVID), the company has submitted an amended protocol to the U.S. Food and Drug Administration (FDA) for the company's ongoing placebo-controlled clinical trial of crofelemer in pediatric MVID patients. MVID patients are born without the ability to absorb the basic nutrients of life, and are therefore subject to a lethal natural history and a lifetime of parenteral support which is associated with toxicities and comorbidities.", "url": "https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/in-support-of-possible-expedited-approval-pathway-for-crofelemer-for-1104582"}, {"symbol": "IBRX", "publishedDate": "2025-11-19 12:29:13", "publisher": "The Motley Fool", "title": "A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know", "image": "https://images.financialmodelingprep.com/news/a-fresh-16-million-bet-on-immunitybio-what-investors-20251119.jpg", "site": "fool.com", "text": "Bought 6,565,709 shares of ImmunityBio, an increase of $16.15 million in position value This new position ranks as the fund's 2nd-largest holding, representing 4.4% of AUM", "url": "https://www.fool.com/coverage/filings/2025/11/19/a-fresh-usd16-million-bet-on-immunitybio-what-investors-should-know/"}, {"symbol": "TNMG", "publishedDate": "2025-11-19 07:00:00", "publisher": "PRNewsWire", "title": "TNL Mediagene (Nasdaq: TNMG) Announces Launch of Digital Media-Commerce Initiative; Begins with Keychron Co-Developed Trackball Device \"Nape Pro\"", "image": "https://images.financialmodelingprep.com/news/tnl-mediagene-nasdaq-tnmg-announces-launch-of-digital-mediacommerce-20251119.jpg", "site": "prnewswire.com", "text": "-The Company today announced the launch of a new digital media-commerce initiative positioning its media brands as co-creators of hardware and creator-focused products -The Company has opened GIZMART, a curated e-commerce platform operated by its media brand Gizmodo Japan, leveraging editorial insight and community trust -As the first project under this initiative, the Company will begin crowdfunding for Nape Pro, a trackball device co-developed with leading global keyboard brand Keychron and based on an original concept by Gizmodo Japan editor Koichiro Amito -Crowdfunding for Nape Pro will start on November 20, 2025, marking the beginning of a broader product-development and commerce strategy the Company aims to expand across Japan and eventually global markets TOKYO , Nov. 19, 2025 /PRNewswire/ -- TNL\u00a0Mediagene (Nasdaq: TNMG) (the \"Company\"), a next-generation digital media and data group in Asia, today announced the launch of a digital media-commerce initiative designed to strengthen the intersection of editorial authority, community trust, and product creation. As the first phase of this multi-year strategy, the Company has opened GIZMART, a curated e-commerce platform operated by its tech-focused media brand Gizmodo Japan.", "url": "https://www.prnewswire.com/news-releases/tnl-mediagene-nasdaq-tnmg-announces-launch-of-digital-media-commerce-initiative-begins-with-keychron-co-developed-trackball-device-nape-pro-302620124.html"}, {"symbol": "IBRX", "publishedDate": "2025-11-19 04:56:50", "publisher": "Seeking Alpha", "title": "ImmunityBio: Checking The Boxes Of A True Commercial-Stage Biotech", "image": "https://images.financialmodelingprep.com/news/immunitybio-checking-the-boxes-of-a-true-commercialstage-biotech-20251119.jpg", "site": "seekingalpha.com", "text": "ImmunityBio shows strong commercial momentum with ANKTIVA, reporting significant revenue growth and improved net loss in Q3. IBRX pipeline progress includes promising data in glioblastoma, NSCLC, non-Hodgkin lymphoma, and a new Phase II trial for long COVID. Despite bullish long-term outlook, near-term risks include ongoing losses, potential dilution, regulatory hurdles, and manufacturing dependencies.", "url": "https://seekingalpha.com/article/4845463-immunitybio-checking-the-boxes-of-a-true-commercial-stage-biotech"}, {"symbol": "PRFX", "publishedDate": "2025-11-18 02:30:59", "publisher": "Defense World", "title": "PainReform (NASDAQ:PRFX) Trading Down 1.3%  \u2013 Here\u2019s Why", "image": "https://images.financialmodelingprep.com/news/painreform-nasdaqprfx-trading-down-13-heres-why-20251118.png", "site": "defenseworld.net", "text": "PainReform Ltd. (NASDAQ: PRFX - Get Free Report) dropped 1.3% during mid-day trading on Monday. The stock traded as low as $0.87 and last traded at $0.8838. Approximately 96,867 shares changed hands during mid-day trading, a decline of 86% from the average daily volume of 695,639 shares. The stock had previously closed at $0.8955. Analyst", "url": "https://www.defenseworld.net/2025/11/18/painreform-nasdaqprfx-trading-down-1-3-heres-why.html"}, {"symbol": "JAGX", "publishedDate": "2025-11-17 10:17:08", "publisher": "Seeking Alpha", "title": "Jaguar Health, Inc. (JAGX) Q3 2025 Earnings Call Prepared Remarks Transcript", "image": "https://images.financialmodelingprep.com/news/jaguar-health-inc-jagx-q3-2025-earnings-call-prepared-20251117.jpg", "site": "seekingalpha.com", "text": "Jaguar Health, Inc. ( JAGX ) Q3 2025 Earnings Call November 17, 2025 8:30 AM EST Company Participants Lisa Conte - Founder, CEO, President & Director Carol Lizak - Chief Financial Officer Presentation Operator Greetings, and welcome to the Jaguar Health's Investor Webcast. [Operator Instructions] As a reminder, this conference is being recorded.", "url": "https://seekingalpha.com/article/4844611-jaguar-health-inc-jagx-q3-2025-earnings-call-prepared-remarks-transcript"}, {"symbol": "JFBR", "publishedDate": "2025-11-17 08:08:00", "publisher": "GlobeNewsWire", "title": "Jeffs' Brands: Jeffs' Brands Holdings Enters Into a Non-Binding MOU for an Exclusive Multi Continent Distribution Agreement of an Electromagnetic Imaging, AI Homeland Security Technology", "image": "https://images.financialmodelingprep.com/news/jeffs-brands-jeffs-brands-holdings-enters-into-a-nonbinding-20251117.jpg", "site": "globenewswire.com", "text": "The 3D, AI Powered Technology Screens 25,000 People Per Hour\u2014Without Stopping Them Tel Aviv, Israel, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd (\u201cJeffs' Brands\u201d or the \u201cCompany\u201d) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, announced today that Jeffs' Brands Holdings Inc., its' wholly owned subsidiary (\u201cJeffs' Brands Holdings\u201d or the \u201cSubsidiary\u201d) has entered into a non-binding Memorandum of Understanding (\u201cMOU\u201d) with Scanary Ltd. (\u201cScanary\u201d), an Israeli deep-tech developer of \u00a03D imaging, electromagnetic, AI-powered threat detection systems, which transaction would mark a strategic pivot into the global homeland-security sector.", "url": "https://www.globenewswire.com/news-release/2025/11/17/3189137/0/en/Jeffs-Brands-Jeffs-Brands-Holdings-Enters-Into-a-Non-Binding-MOU-for-an-Exclusive-Multi-Continent-Distribution-Agreement-of-an-Electromagnetic-Imaging-AI-Homeland-Security-Technolo.html"}, {"symbol": "JAGX", "publishedDate": "2025-11-17 08:00:00", "publisher": "Accesswire", "title": "Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue", "image": "https://images.financialmodelingprep.com/news/jaguar-health-reports-third-quarter-2025-financials-net-q3-20251117.jpg", "site": "accessnewswire.com", "text": "Initial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure due to microvillus inclusion disease (MVID), reducing the volume of the total parenteral support (PS) necessary for them to survive, though with associated toxicity; Groundbreaking PS reduction of up to 37%; No approved treatments exist for MVID Company completed meeting with FDA October 2, 2025 for advice on possible expedited approval pathway to advance its ongoing placebo-controlled trial of crofelemer for potential approval for treatment of MVID REMINDER: Today Jaguar to host investor webcast at 8:30 a.m. Eastern regarding Q3 2025 financials and company updates; Click here to register SAN FRANCISCO, CA / ACCESS Newswire / November 17, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\" or the \"Company\") today reported its consolidated third-quarter 2025 financial results.", "url": "https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-reports-third-quarter-2025-financials-net-q3-2025-reven-1102680"}, {"symbol": "JAGX", "publishedDate": "2025-11-14 09:00:00", "publisher": "Accesswire", "title": "Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates", "image": "https://images.financialmodelingprep.com/news/jaguar-health-to-hold-investor-webcast-monday-november-17-20251114.jpg", "site": "accessnewswire.com", "text": "Click here to register Company plans to file its Earnings Report on November 14, 2025 on Form 10-Q for the quarter ended September 30, 2025 SAN FRANCISCO, CA / ACCESS Newswire / November 14, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, November 17, 2025, at 8:30 a.m. Eastern to review third-quarter 2025 financials and provide corporate updates.", "url": "https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-to-hold-investor-webcast-monday-november-17-at-8-30-am-1102260"}, {"symbol": "VERO", "publishedDate": "2025-11-13 10:01:31", "publisher": "Seeking Alpha", "title": "Venus Concept Inc. (VERO) Q3 2025 Earnings Call Transcript", "image": "https://images.financialmodelingprep.com/news/venus-concept-inc-vero-q3-2025-earnings-call-transcript-20251113.jpg", "site": "seekingalpha.com", "text": "Venus Concept Inc. ( VERO ) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST Company Participants Rajiv Kanishka De Silva - CEO & Director Domenic Penna - Executive VP & CFO Presentation Operator Good day, ladies and gentlemen, and welcome to the Third Quarter 2025 Earnings Conference Call for Venus Concept Inc. [Operator Instructions] Please note that this conference call is being recorded and that the recording will be available on the company's website for replay. Before we begin, I would like to remind everyone that our remarks and responses to your questions may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated including those identified in the Risk Factors section of our most recent annual report on Form 10-K filed with the Securities and Exchange Commission.", "url": "https://seekingalpha.com/article/4843119-venus-concept-inc-vero-q3-2025-earnings-call-transcript"}, {"symbol": "IBRX", "publishedDate": "2025-11-13 09:00:00", "publisher": "Business Wire", "title": "New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations", "image": "https://images.financialmodelingprep.com/news/new-survey-reveals-nonmuscle-invasive-bladder-cancer-patients-seek-20251113.jpg", "site": "businesswire.com", "text": "CULVER CITY, Calif.--(BUSINESS WIRE)--A new U.S. survey conducted by The Harris Poll on behalf of ImmunityBio, Inc. (NASDAQ: IBRX) reveals that many people living with non-muscle invasive bladder cancer (NMIBC) feel left out of critical treatment conversations. Fewer than one in five patients surveyed (18%) report their healthcare providers (HCPs) discuss all available treatment options during most or every visit. More than four in five (84%) believe immunotherapy has fewer side effects than ch.", "url": "https://www.businesswire.com/news/home/20251113695968/en/New-Survey-Reveals-Non-Muscle-Invasive-Bladder-Cancer-Patients-Seek-More-Care-Conversations/"}]